



INVESTOR IN PEOPLE

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.



Signed *Andrews*

Dated 28 August 2003

THIS PAGE BLANK (USPTO)



144PR03 E799820-1 001298
P01/7700 0.00-0308460.5

The Patent Office

Cardiff Road
Newport
South Wales
NP10 8QQ

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

1. Your reference

PC25420-PRV2

2. Patent application number

(The Patent Office will fill in this part)

0308460.5

3. Full name, address and postcode of the or of each applicant (underline all surnames)

PFIZER LIMITED
Ramsgate Road,
Sandwich,
Kent, CT13 9NJ

Patents ADP number (if you know it)

6842673001
United Kingdom

If the applicant is a corporate body, give the country/state of its incorporation

4. Title of the invention

MORPHOLINE DOPAMINE AGONISTS

5. Name of your agent (if you have one)

Mr. M. D. Ness

"Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode)

UK Patent Department
Pfizer Limited,
Ramsgate Road,
Sandwich, Kent,
CT13 9NJ
United Kingdom

Patents ADP number (if you know it)

1271001

6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or of each of these earlier applications and (if you know it) the or each application number

Country

Priority application number
(if you know it)

Date of filing
(day / month / year)

7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application

Number of earlier application

Date of filing
(day / month / year)

8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer 'Yes' if:

- a) any applicant named in part 3 is not an inventor, or
 - b) there is an inventor who is not named as an applicant, or
 - c) any named applicant is a corporate body.
- See note (d))

Patents Form 1/77

Enter the number of sheets for any of the following items you are filing with this form.
Do not count copies of the same document

Continuation sheets of this form

Description	86
Claim(s)	0
Abstract	0
Drawing(s)	0

10. If you are also filing any of the following, state how many against each item.

Priority documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (Patents Form 7/77)

Request for preliminary examination and search (Patents Form 9/77)

Request for substantive examination (Patents Form 10/77)

Any other documents
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature

M.D. Ness

Date

11th April 2003

12. Name and daytime telephone number of person to contact in the United Kingdom Mr. M. D. Ness 01034.648104

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes


- If you need help to fill in this form or you have any questions, please contact the Patent Office on 08459 500505.*
- Write your answers in capital letters using black ink or you may type them.*
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.*
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.*
- Once you have filled in the form you must remember to sign and date it.*
- For details of the fee and ways to pay please contact the Patent Office.*

Morpholine Dopamine Agonists

The present invention relates to a class of dopamine agonists, more particularly
5 a class of agonists that are selective for D3 over D2. These compounds are
useful for the treatment and/or prevention of sexual dysfunction, for example
female sexual dysfunction (FSD), in particular female sexual arousal disorder
(FSAD) and male sexual dysfunction, in particular male erectile dysfunction
(MED). Male sexual dysfunction as referred to herein is meant to include
10 ejaculatory disorders such as premature ejaculation, anorgasmia (unable to
achieve orgasm) or desire disorders such as hypoactive sexual desire disorder
(lack of interest in sex). These compounds are also useful in treating
neuropsychiatric disorders and neurodegenerative disorders.

15

The present invention provides for compounds of formula (I), (Ia) and (Ib)



Wherein:

A is selected from C-X and N,

B is selected from C-Y and N,

R¹ is selected from H and (C₁-C₆)alkyl,

X is selected from HO, C(O)NH₂, NH₂

5 Y is selected from H, HO, Cl and F

Z is selected from H, HO, F, CONH₂ and CN;

And pharmaceutically acceptable salts, solvates and prodrugs thereof;

With the provisos that:

for a compound of formula (I), (Ia) or (Ib), when A is C-X, B is C-Y, and R¹ is H

10 or (C₁-C₆)alkyl, at least one of X, Y and Z must be OH;

for a compound of formula (I), when A is C-X and B is C-Y, Y is H, Z is H, and R¹ is H, then X cannot be OH.

The pharmaceutically acceptable salts of the compounds of the formula (I)

15 include the acid addition and the base salts thereof.

A pharmaceutically acceptable salt of a compound of the formula (I) may be readily prepared by mixing together solutions of a compound of the formula (I) and the desired acid or base, as appropriate. The salt may precipitate from

20 solution and be collected by filtration or may be recovered by evaporation of the solvent.

Suitable acid addition salts are formed from acids which form non-toxic salts and examples are the hydrochloride, hydrobromide, hydroiodide, sulphate, bisulphate, nitrate, phosphate, hydrogen phosphate, acetate, maleate,

25 fumarate, lactate, tartrate, citrate, gluconate, succinate, saccharate, benzoate, methanesulphonate, ethanesulphonate, benzenesulphonate, p-toluenesulphonate and pamoate salts.

30 Suitable base salts are formed from bases which form non-toxic salts and examples are the sodium, potassium, aluminium, calcium, magnesium, zinc and diethanolamine salts.

For a review on suitable salts see Berge et al, J. Pharm. Sci., 66, 1-19, 1977.

The pharmaceutically acceptable solvates of the compounds of the formula (I)
5 include the hydrates thereof.

Also included within the present scope of the compounds of the formula (I) are polymorphs thereof.

- 10 A compound of the formula (I) contains one or more asymmetric carbon atoms and therefore exists in two or more stereoisomeric forms.
- Separation of diastereoisomers may be achieved by conventional techniques, e.g. by fractional crystallisation, chromatography or H.P.L.C. of a stereoisomeric mixture of a compound of the formula (I) or a suitable salt or
15 derivative thereof. An individual enantiomer of a compound of the formula (I) may also be prepared from a corresponding optically pure intermediate or by resolution, such as by H.P.L.C. of the corresponding racemate using a suitable chiral support or by fractional crystallisation of the diastereoisomeric salts formed by reaction of the corresponding racemate with a suitable optically
20 active acid or base, as appropriate.

Preferred compounds of the present invention are compounds of formula (Ia) and (Ib)

- 25 Particularly preferred are compounds of formula (Ia)

Preferably A is C-X and B is C-Y or N
More preferably A is C-X and B is C-Y

- 30 Preferably R¹ is selected from H, methyl and ethyl.
More preferably R¹ is H.

Preferably X is OH

Preferably Y is H

- 5 Preferably Z is selected from H, HO and F.
More preferably Z is selected from H or OH.


Particularly preferred are compounds (and salts thereof) of the present invention exemplified herein; most preferred are:


10

- | | |
|--|---------------|
| R-(-)-3-(4-Propylmorpholin-2-yl)phenol | (Example 7a) |
| S-(+)-3-(4-Propylmorpholin-2-yl)phenol | (Example 7b) |
| R-5-(4-Propylmorpholin-2-yl)benzene-1, 3-diol | (Example 15a) |
| S-5-(4-Propylmorpholin-2-yl)benzene-1, 3-diol | (Example 15b) |
| 15 R-(+)-2-Fluoro-5-(4-propylmorpholin-2-yl)phenol | (Example 23a) |
| S-(-)-2-Fluoro-5-(4-propylmorpholin-2-yl)phenol | (Example 23b) |
| 2-Bromo-4-(4-propylmorpholin-2-yl)phenol | (Example 30) |
| 2-Hydroxy-5-(4-propylmorpholin-2-yl)benzamide | (Example 35) |
| 2-Nitro-4-(4-propylmorpholin-2-yl)phenol | (Example 36) |
| 20 2-Amino-4-(4-propylmorpholin-2-yl)phenol | (Example 37) |
| 5-(4-propylmorpholin-2-yl)pyridin-2-ylamine | (Example 44) |
| 2-Chloro-5-(4-propyl-morphlin-2-yl)-phenol | (Example 54) |

- Compounds of the invention may be prepared, in known manner, in a variety of
- 25 ways. The routes below illustrate methods of synthesising compounds of formula (I); the skilled man will appreciate that compounds of formula (Ia) and (Ib) may be isolated with appropriate resolution techniques.

- Compounds of general formula I where A is C-X, B is C-Y, R¹ is H or (C₁-
- 30 C₆)alkyl and where X, Y and Z are as described herein may be prepared according to reaction scheme 1.





Scheme 1

5

Compounds of formula (III) may be prepared by reacting an aldehyde of formula II with i) a cyanide source or nitromethane followed by ii) reduction with borane, lithium aluminium hydride or hydrogenation. Some compounds of formula II and III are also commercially available.

10

Compounds of formula (IV) may be prepared by reacting compounds of formula (III) with iii), acid chlorides in the presence of a suitable base such as triethylamine or 4-methylmorpholine. Typical reaction conditions comprise 1.0 equivalents of amine (III), 1.2-2.0 equivalents of base (preferably triethylamine),

15 1.1-1.3 equivalents of acid chloride in dichloromethane at 25°C.


Compounds of formula (V) may be prepared by reducing compounds of formula (IV) with iv), reducing agents such as borane or lithium aluminium hydride. Typical conditions comprise 1.0 equivalents of amide (IV), 1.2-3.0 equivalents of borane in THF at reflux. Compounds of formula (V) can also be made by
5 reductive animation of compounds of formula (III) with a suitable aldehyde in the presence of sodium cyanoborohydride.


Compounds of formula (VI) may be prepared by reacting compounds of formula V with v), chloroacetyl chloride or 2-substituted chloroacetyl chlorides (such as
10 2-chloropropionyl chloride or 2-chlorobutyryl chloride) in the presence of base such as triethylamine, sodium carbonate and potassium hydroxide. Typical conditions comprise 1.0 equivalents of amine IV, 1.0-1.3 equivalents of acid chloride, 1.2-2.0 equivalents of triethylamine in dichloromethane at 25°C, the crude reaction mixture is then dissolved in IPA with 1.2-3.0 equivalents of
15 aqueous potassium hydroxide.

Compounds of formula (I) may be prepared by reacting compounds of formula (VI) with vi), reducing agents such as borane or lithium aluminium hydride. Typical conditions comprise 1.0 equivalents of amide VI, 1.2-3.0 equivalents of
20 borane in THF at reflux.

The skilled man will appreciate that due to one of X, Y or Z being a hydroxy group, it will be necessary to protect the hydroxy group(s) with a suitable protecting group throughout the transformations of scheme 1, then remove the
25 protecting group. Methods for deprotection of a phenol group depend on the protecting group. For examples of protection/deprotection methodology see "Protective groups in Organic synthesis", TW Greene and PGM Wutz. For example, where the hydroxy is protected as a methyl ether, deprotection conditions comprise refluxing in 48% aqueous HBr for 1-24 hours, or by stirring
30 with borane tribromide in dichloromethane for 1-24 hours. Alternatively where the hydroxy is protected as a benzyl ether, deprotection conditions comprise hydrogenation with a palladium catalyst under a hydrogen atmosphere.

- Compounds of general formula (I) where one of A or B is N, R^1 is H and X, Y, and Z are as described herein, with the proviso that one of X, Y or Z is NH_2 , may be prepared according to reaction scheme 2. Scheme is illustrated where
- 5 B is C-Y and where Y is NH_2 ; the skilled man will understand that the alternative compounds are equally practicable.





Scheme 2

- 5 Compounds of formula (VII) may be prepared using the process as described in JP2001048864.

Compounds of formula (VIII) may be prepared by reacting epoxide (VII) with
vii), propylamine. Typical reaction conditions comprise stirring the epoxide with
10 excess amine either neat or in dimethylsulphoxide.

Compounds of formula (IX) may be prepared by reacting compounds of formula
(VIII) with v), chloroacetyl chloride in the presence of base such as
triethylamine, sodium carbonate and potassium hydroxide. Typical conditions
15 comprise 1.0 equivalents of amine (VIII), 1.2-2.0 equivalents of triethylamine in

dichloromethane at 25°C, the crude reaction mixture is then dissolved in IPA with 1.2-3.0 equivalents of aqueous potassium hydroxide.

Compounds of formula (X) may be prepared by reacting compounds of formula (IX) with reducing agents such as lithium aluminium hydride. Typical conditions comprise 1.0 equivalents of amide (X), 1.2 equivalents of lithium aluminium hydride in THF at reflux.

Compounds of formula (I) may be prepared by ix), deprotection. Typical conditions comprise 1.0 equivalents of compound X and 5 equivalents of hydroxylamine hydrochloride in ethanol at reflux.

All of the above reactions and the preparations of novel starting materials using in the preceding methods are conventional and appropriate reagents and reaction conditions for their performance or preparation as well as procedures for isolating the desired products will be well-known to those skilled in the art with reference to literature precedents and the Examples and Preparations hereto.

The compounds of the present invention have utility as selective D3 agonists in the treatment of disease states. There are a number of compounds with activity as both D2 and D3 agonists; however the use of such compounds is associated with a large number of side effects including nausea, emesis, syncope, hypotension and bradycardia, some of which are a cause for serious concern.

25

It was previously held that the efficacy of the prior art compounds stemmed from their ability to agonise D2; however D2 agonism is implicated as a cause of the side effects detailed above.

The present invention provides a class of selective D3 agonists. Serendipitously, these have been found to be efficacious, whilst reducing the side effects associated with unselective prior art compounds.

Compounds of present invention are useful in treating sexual dysfunction, female sexual dysfunction, including hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder and sexual pain disorder; male erectile dysfunction, hypertension, neurodegeneration, psychiatric disorders, depression (e.g. depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, paediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression and grumpy old man syndrome), generalized anxiety disorder, phobias (e.g. agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, premature ejaculation, eating disorders (e.g. anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g. addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), cluster headache, migraine, pain, Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g. dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g. dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g. hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders (involving changes in motility and secretion), negative symptoms of schizophrenia, premenstrual syndrome, fibromyalgia syndrome, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, male impotence, attention deficit hyperactivity disorder (ADHD), chronic paroxysmal hemicrania, headache (associated with vascular disorders), emotional lability, pathological crying, sleeping disorder (cataplexy) and shock.

Compounds of the present invention are particularly suitable for treating female sexual dysfunction, male erectile dysfunction, neurodegeneration, depression and psychiatric disorders.

The compounds of the present invention are useful in male sexual dysfunction, particularly male erectile dysfunction. Male erectile dysfunction (MED), otherwise known as male erectile disorder, is defined as:

5 *"the inability to achieve and/or maintain a penile erection for satisfactory sexual performance" (NIH Consensus Development Panel on Impotence, 1993)"*

10 It has been estimated that the prevalence of erectile dysfunction (ED) of all degrees (minimal, moderate and complete impotence) is 52% in men 40 to 70 years old, with higher rates in those older than 70 (Melman *et al* 1999, J. Urology, 161, p5-11). The condition has a significant negative impact on the quality of life of the individual and their partner, often resulting in increased anxiety and tension which leads to depression and low self-esteem. Whereas
15 two decades ago, MED was primarily considered to be a psychological disorder (Benet *et al* 1994 Comp. Ther., 20: 669-673), it is now known that for the majority of individuals there is an underlying organic cause. As a result, much progress has been made in identifying the mechanism of normal penile erection and the pathophysiologies of MED.

20 Penile erection is a haemodynamic event which is dependent upon the balance of contraction and relaxation of the corpus cavernosal smooth muscle and vasculature of the penis (Lerner *et al* 1993, J. Urology, 149, 1256-1255). Corpus cavernosal smooth muscle is also referred to herein as corporal smooth
25 muscle or in the plural sense corpus cavernosa. Relaxation of the corpus cavernosal smooth muscle leads to an increased blood flow into the trabecular spaces of the corpus cavernosa, causing them to expand against the surrounding tunica and compress the draining veins. This produces a vast elevation in blood pressure which results in an erection (Naylor, 1998, J.
30 Urology, 81, 424-431).

The changes that occur during the erectile process are complex and require a high degree of co-ordinated control involving the peripheral and central nervous systems, and the endocrine system (Naylor, 1998, J. Urology, 81, 424-431). Corporal smooth muscle contraction is modulated by sympathetic
5 noradrenergic innervation via activation of postsynaptic α_1 adrenoceptors. MED may be associated with an increase in the endogenous smooth muscle tone of the corpus cavernosum. However, the process of corporal smooth muscle relaxation is mediated partly by non-adrenergic, non-cholinergic (NANC) neurotransmission. There are a number of other NANC neurotransmitters
10 found in the penis, other than NO, such as calcitonin gene related peptide (CGRP) and vasoactive intestinal peptide (VIP). The main relaxing factor responsible for mediating this relaxation is nitric oxide (NO), which is synthesised from L-arginine by nitric oxide synthase (NOS) (Taub *et al* 1993 Urology, 42, 698-704). It is thought that reducing corporal smooth muscle tone
15 may aid NO to induce relaxation of the corpus cavernosum. During sexual arousal in the male, NO is released from neurones and the endothelium and binds to and activates soluble guanylate cyclase (sGC) located in the smooth muscle cells and endothelium, leading to an elevation in intracellular cyclic guanosine 3',5'-monophosphate (cGMP) levels. This rise in cGMP leads to a
20 relaxation of the corpus cavernosum due to a reduction in the intracellular calcium concentration ($[Ca^{2+}]_i$), via unknown mechanisms thought to involve protein kinase G activation (possibly due to activation of Ca^{2+} pumps and Ca^{2+} -activated K^+ channels).

25 Multiple potential sites have been identified within the central nervous system for the modulation of sexual behaviour. The key neurotransmitters are thought to be serotonin, norepinephrine, oxytocin, nitric oxide and dopamine. By mimicking the actions of one of these key neurotransmitters sexual function may be adjusted. Dopamine D3 receptors are expressed almost exclusively in
30 the limbic are of the brain, regions involved in the reward, emotional and cognitive processes.

Without being bound by any theory, it appears that "due to its role in the control of locomotor activity, the integrity of the nigrostriatal dopaminergic pathway is also essential for the display of copulatory behaviour. Somehow, more specific to sexual function, it is likely that dopamine can trigger penile erection by acting
5 on oxytocinergic neurons located in the paraventricular nucleus of the hypothalamus, and perhaps on the pro-erectile sacral parasympathetic nucleus within the spinal cord". It now appears that the significant site is D3 and not as previously thought, D2.

10 In essence, D3 is an initiator of sexual behaviour.

Accordingly, the present invention provides for, the use of a compound of formula (I) in the preparation of a medicament for the treatment or prevention of erectile dysfunction.

15

Patients with mild to moderate MED should benefit from treatment with the compounds according to the present invention, and patients with severe MED may also respond. However, early investigations suggest that the responder rate of patients with mild, moderate and severe MED may be greater with a
20 selective D3 agonist/PDE5 inhibitor combination. Mild, moderate and severe MED will be terms known to the man skilled in the art, but guidance can be found in The Journal of Urology, vol. 151, 54-61 (Jan 1994).

Early investigations suggest the below mentioned MED patient groups should
25 benefit from treatment with a selective D3 agonist and a PDE5i (or other combination set out hereinafter). These patient groups, which are described in more detail in Clinical Andrology vol. 23, no.4, p773-782 and chapter 3 of the book by I. Eardley and K. Sethia "Erectile Dysfunction-Current Investigation and Management, published by Mosby-Wolfe, are as follows: psychogenic, organic,
30 vascular, endocrinologic, neurogenic, arteriogenic, drug-induced sexual dysfunction (lactogenic) and sexual dysfunction related to cavernosal factors, particularly venogenic causes.

Accordingly the present invention provides for the use of a compound of formula (I), (Ia) or (Ib) in the preparation of a medicament in combination with a PDE5 inhibitor for the treatment of erectile dysfunction.

5 Suitable PDE5 inhibitors are described herein.

The compounds of the present invention are useful in the treatment or prevention of female sexual dysfunction (FSD), particularly FSAD.

- 10 In accordance with the invention, FSD can be defined as the difficulty or inability of a woman to find satisfaction in sexual expression. FSD is a collective term for several diverse female sexual disorders (Leiblum, S.R. (1998) - Definition and classification of female sexual disorders. *Int. J. Impotence Res.*, **10**, S104-S106; Berman, J.R., Berman, L. & Goldstein, I.
- 15 (1999) - Female sexual dysfunction: Incidence, pathophysiology, evaluations and treatment options. *Urology*, **54**, 385-391.). The woman may have lack of desire, difficulty with arousal or orgasm, pain with intercourse or a combination of these problems. Several types of disease, medications, injuries or psychological problems can cause FSD. Treatments in development are
- 20 targeted to treat specific subtypes of FSD, predominantly desire and arousal disorders.

- The categories of FSD are best defined by contrasting them to the phases of normal female sexual response: desire, arousal and orgasm (Leiblum, S.R.
- 25 (1998) - Definition and classification of female sexual disorders. *Int. J. Impotence Res.*, **10**, S104-S106). Desire or libido is the drive for sexual expression. Its manifestations often include sexual thoughts either when in the company of an interested partner or when exposed to other erotic stimuli. Arousal is the vascular response to sexual stimulation, an important component
- 30 of which is genital engorgement and includes increased vaginal lubrication, elongation of the vagina and increased genital sensation/sensitivity. Orgasm is the release of sexual tension that has culminated during arousal.

Hence, FSD occurs when a woman has an inadequate or unsatisfactory response in any of these phases, usually desire, arousal or orgasm. FSD categories include hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorders and sexual pain disorders. Although the compounds of the invention will improve the genital response to sexual stimulation (as in female sexual arousal disorder), in doing so it may also improve the associated pain, distress and discomfort associated with intercourse and so treat other female sexual disorders.

10

Hypoactive sexual desire disorder is present if a woman has no or little desire to be sexual, and has no or few sexual thoughts or fantasies. This type of FSD can be caused by low testosterone levels, due either to natural menopause or to surgical menopause. Other causes include illness, medications, fatigue, depression and anxiety.

15

Female sexual arousal disorder (FSAD) is characterised by inadequate genital response to sexual stimulation. The genitalia do not undergo the engorgement that characterises normal sexual arousal. The vaginal walls are poorly lubricated, so that intercourse is painful. Orgasms may be impeded. Arousal disorder can be caused by reduced oestrogen at menopause or after childbirth and during lactation, as well as by illnesses, with vascular components such as diabetes and atherosclerosis. Other causes result from treatment with diuretics, antihistamines, antidepressants e.g. selective serotonin re-uptake inhibitors (SSRIs) or antihypertensive agents.

20

25

Sexual pain disorders (includes dyspareunia and vaginismus) is characterised by pain resulting from penetration and may be caused by medications which reduce lubrication, endometriosis, pelvic inflammatory disease, inflammatory bowel disease or urinary tract problems.

30

As previously discussed, D3 is thought to be an initiator of sexual behaviour. The clitoris is considered to be a homologue of the penis (Levin, R.J. (1991), *Exp. Clin. Endocrinol.*, **98**, 61-69); the same mechanism that provides provides an erectile response in the male produces an increase in genital blood flow in the female with an associated effect upon FSD. In addition there are changes in proceptivity and receptivity.

Thus, in accordance with a preferred aspect of the invention, there is provided use of a compound of formula (I), (Ia) or (Ib) in the preparation of a medicament for the treatment or prophylaxis of female sexual dysfunction, more particularly hypoactive sexual desire disorder, sexual arousal disorder, orgasmic disorder and sexual pain disorder.

Preferably the compounds of formula (I) are useful in the treatment or prophylaxis of sexual arousal disorder, orgasmic disorder, and hypoactive sexual desire disorder, and most preferably in the treatment or prophylaxis of sexual arousal disorder.

In a preferred embodiment the compounds of formula (I), (Ia) and (Ib) are useful in the treatment of a subject with female sexual arousal disorder and concomitant hypoactive sexual desire disorder.

The Diagnostic and Statistical Manual (DSM) IV of the American Psychiatric Association defines Female Sexual Arousal Disorder (FSAD) as being:

"... a persistent or recurrent inability to attain or to maintain until completion of the sexual activity adequate lubrication-swelling response of sexual excitement. The disturbance must cause marked distress or interpersonal difficulty. ..."

The arousal response consists of vasocongestion in the pelvis, vaginal lubrication and expansion and swelling of the external genitalia. The disturbance causes marked distress and/or interpersonal difficulty.

FSAD is a highly prevalent sexual disorder affecting pre-, peri- and post-menopausal (\pm hormone replacement therapy (HRT)) women. It is associated with concomitant disorders such as depression, cardiovascular diseases,
5 diabetes and urogenital (UG) disorders.

The primary consequences of FSAD are lack of engorgement/swelling, lack of lubrication and lack of pleasurable genital sensation. The secondary consequences of FSAD are reduced sexual desire, pain during intercourse and
10 difficulty in achieving an orgasm.

It has recently been hypothesised that there is a vascular basis for at least a proportion of patients with symptoms of FSAD (Goldstein *et al.*, Int. J. Impot. Res., 10, S84-S90, 1998) with animal data supporting this view (Park *et al.*, Int.
15 J. Impot. Res., 9, 27-37, 1997).

R.J. Levin teaches us that because "... *male and female genitalia develop embryologically from the common tissue anlagen, [that] male and female genital structures are argued to be homologues of one another. Thus the clitoris is the*
20 *penile homologue and the labia homologues of the scrotal sac. ...*" (Levin, R.J. (1991), *Exp. Clin. Endocrinol.*, **98**, 61-69).

Drug candidates for treating FSAD, which are under investigation for efficacy, are primarily erectile dysfunction therapies that promote circulation to male
25 genitalia. .

The compounds of the present invention are advantageous by providing a means for restoring a normal sexual arousal response - namely increased genital blood flow leading to vaginal, clitoral and labial engorgement. This will
30 result in increased vaginal lubrication via plasma transudation, increased vaginal compliance and increased genital sensitivity. Hence, the present

invention provides a means to restore, or potentiate, the normal sexual arousal response.

Thus, in accordance with a preferred aspect of the invention, there is provided
5 use of a compound of formula (I), (Ia) or (Ib) in the preparation of a medicament for the treatment or prophylaxis of female sexual arousal disorder.

By female genitalia herein we mean: "The genital organs consist of an internal and external group. The internal organs are situated within the pelvis and
10 consist of ovaries, the uterine tubes, uterus and the vagina. The external organs are superficial to the urogenital diaphragm and below the pelvic arch. They comprise the mons pubis, the labia majora and minora pudendi, the clitoris, the vestibule, the bulb of the vestibule, and the greater vestibular glands" (Gray's Anatomy, C.D. Clemente, 13th American Edition).

15

The compounds of the invention find application in the following sub-populations of patients with FSD: the young, the elderly, pre-menopausal, peri-menopausal, post-menopausal women with or without hormone replacement
20 therapy.

The compounds of the invention find application in patients with FSD arising from:-

- i) Vasculogenic etiologies e.g. cardiovascular or atherosclerotic diseases,
25 hypercholesterolemia, cigarette smoking, diabetes, hypertension, radiation and perineal trauma, traumatic injury to the iliohypogastric pudendal vascular system.
- ii) Neurogenic etiologies such as spinal cord injuries or diseases of the central nervous system including multiple sclerosis, diabetes,
30 Parkinsonism, cerebrovascular accidents, peripheral neuropathies, trauma or radical pelvic surgery.

- iii) Hormonal/endocrine etiologies such as dysfunction of the hypothalamic/pituitary/gonadal axis, or dysfunction of the ovaries, dysfunction of the pancreas, surgical or medical castration, androgen deficiency, high circulating levels of prolactin e.g. hyperprolactinemia,
5 natural menopause, premature ovarian failure, hyper and hypothyroidism.
- iv) Psychogenic etiologies such as depression, obsessive compulsive disorder, anxiety disorder, postnatal depression/"Baby Blues", emotional and relational issues, performance anxiety, marital discord, dysfunctional
10 attitudes, sexual phobias, religious inhibition or a traumatic past experiences.
- v) Drug-induced sexual dysfunction resulting from therapy with selective serotonin reuptake inhibitors (SSRIs) and other antidepressant therapies (tricyclics and major tranquillizers), anti-hypertensive therapies, sympatholytic
15 drugs, chronic oral contraceptive pill therapy.

The Compounds of the present invention are also useful in the treatment of depression.

- 20 Dopamine D3 receptors are expressed almost exclusively in the limbic area of the brain, regions involved in reward, emotional and cognitive processes. Chronic treatment with several classes of antidepressants are known to increase the expression of D3 in the limbic area, and antidepressant effects of desipramine can be blocked by sulpride (D2/D3 antagonist) when injected to
25 nucleus accumbens (area rich in D3) but not caudate-putamen (area rich in dopamine D2 receptors). In addition, antidepressant effects were observed preclinical models of depression and in patients treated with pramipexole, a D3-preferring agonist. The available information suggests that D3 receptors mediate the anti-depressant activity and that selective D3 receptor agonists
30 represent a new class of antidepressant drugs. Since antidepressants are known to be effective in other psychiatric disorders, D3 agonists would have the potential to treat psychiatric diseases.

The present invention provides for the use of a selective D3 agonist in the preparation of a medicament for the treatment of depression and psychiatric diseases.

5

Preferably said D3 agonist exhibit a functional potency at D3 receptor expressed as an EC50, lower than 1000nM, more preferably lower than 100nM, yet more preferably lower than 50nM, most preferably lower than 10nM.

- 10 Preferably said D3 agonist has a selectivity for D3 over D2, wherein said dopamine D3 receptor agonist is at least about 15-times, preferably at least about 27-times, more preferably at least about 30-times, most preferably at least about 100-times more functionally selective for a dopamine D3 receptor as compared with a dopamine D2 receptor

15

Suitable conditions include depression (e.g. depression in cancer patients, depression in Parkinson's patients, postmyocardial infarction depression, subsyndromal symptomatic depression, depression in infertile women, paediatric depression, major depression, single episode depression, recurrent depression, child abuse induced depression, post partum depression and grumpy old man syndrome), generalized anxiety disorder, phobias (e.g. agoraphobia, social phobia and simple phobias), posttraumatic stress syndrome, avoidant personality disorder, eating disorders (e.g. anorexia nervosa and bulimia nervosa), obesity, chemical dependencies (e.g. addictions to alcohol, cocaine, heroin, phenobarbital, nicotine and benzodiazepines), Alzheimer's disease, obsessive-compulsive disorder, panic disorder, memory disorders (e.g. dementia, amnestic disorders, and age-related cognitive decline (ARCD)), Parkinson's diseases (e.g. dementia in Parkinson's disease, neuroleptic-induced parkinsonism and tardive dyskinesias), endocrine disorders (e.g. hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, negative symptoms of schizophrenia, stress incontinence, Tourette's syndrome, trichotillomania, kleptomania, attention deficit

hyperactivity disorder (ADHD), chronic paroxysmal hemicrania, emotional lability, pathological crying, sleeping disorder (cataplexy) and shock.

In a preferred embodiment, the present invention provides for the use of a
5 compound of formula (I), (Ia) and (Ib) in the preparation of a medicament for the treatment of depression or psychiatric disorders.

Suitable depressive conditions and psychiatric disorders are described above.

10 The compounds of the present invention also have utility in the treatment of neurodegeneration; sources of neurodegeneration include neurotoxin poisoning; vision loss caused by neurodegeneration of the visual pathway, such as by a stroke in the visual pathway eg in retina, optic nerve and/or occipital lobe; epileptic seizures; and from impairment of glucose and/or oxygen supply
15 to the brain.

Accordingly the present invention provides for the use of a selective D3 agonist in the preparation of a medicament for the treatment of neurodegeneration.

20 Preferably said D3 agonist exhibit a functional potency at D3 receptor expressed as an EC50, lower than 1000nM, more preferably lower than 100nM, yet more preferably lower than 50nM, most preferably lower than 10nM.

Preferably said D3 agonist has a selectivity for D3 over D2, wherein said
25 dopamine D3 receptor agonist is at least about 15-times, preferably at least about 27-times, more preferably at least about 30-times, most preferably at least about 100-times more functionally selective for a dopamine D3 receptor as compared with a dopamine D2 receptor

30 In a preferred embodiment, the D3 agonist is a compound of formula (I), (Ia) or (Ib)

In addition to their role in treating Sexual dysfunction, depression, neurodegeneration and psychiatric disorders, the compounds of the present invention are likely to be efficacious in a number of additional indications.

- 5 Accordingly, the present invention provides for the use of compounds of formula (I), (Ia) or (Ib) in the preparation of a medicament for the treatment of hypertension, premature ejaculation, obesity, cluster headache, migraine, pain, endocrine disorders (e.g. hyperprolactinaemia), vasospasm (particularly in the cerebral vasculature), cerebellar ataxia, gastrointestinal tract disorders
10 (involving changes in motility and secretion), premenstrual syndrome, fibromyalgia syndrome, stress incontinence, trichotillomania and chronic paroxysmal hemicrania, headache (associated with vascular disorders).

D3/D2 AGONIST BIND ASSAY

15

Gonzalez *et al* (Eup. J Pharmacology 272 (1995) R1-R3) discloses an assay for determining the binding capability of a compound at D3 and/or D2 dopamine receptors and thus the binding selectivity of such compounds. This assay is, thus, herein referred to as a binding assay.

20

D3/D2 AGONIST FUNCTIONAL ASSAY

A suitable assay for determining functionally the activity of a compound at D3 and/or D2 dopamine receptors is detailed hereinbelow.

25

Compounds are evaluated as agonists or antagonists at the dopamine D2 and D3 receptors by looking at cAMP levels in a GH4C1 and CHO cell-line expressing the human D2 and D3 receptors, respectively.

30 EXPERIMENTAL PROCEDURES

Inhibition Via Dopamine D3 Receptors of Forskolin-Stimulated Adenylate Cyclase Activity

MATERIALS

Cell culture media:

5

hD ₃ CHO Medium
DMEM, high glucose (Sigma D5671)
2mM L-Glutamine (Sigma G7513)
10% dialyzed FBS (Sigma F0392)

hD₃CHO (Chinese hamster Ovary) cells expressing the human Dopamine D₃ receptor were generated in house. These cells are deficient in the *dihydrofolate reductase* gene.

10

Media is made up fresh every week as below, and filtered through a 0.22 μ m filter before use. Media is stored at 4°C and warmed to 37°C prior to addition to the cells.

15 **Cell Dissociation Solution (CDS):** (Sigma C-5914)

5ml used to harvest cells from 225cm² flask (37°C 5 min for hD₂LGH4C1 cells and 10 minutes for hD₃CHO cells).

Phosphate Buffered Saline (PBS): (Gibco. 14040-091)

20

Trypan Blue: (Sigma T8154)

Forskolin (Calbiochem 344273)

25 Dissolved to a concentration of 20mM in distilled water. (This stock is stored at +4°C). 4x assay stock of 40 μ M is made by carrying out a 500-fold dilution in PBS buffer. 25 μ l of the 40 μ M stock is added to a final assay volume of 100 μ l, yielding a final assay concentration of 10 μ M.

Test compounds

Dissolved in 100% DMSO to yield a stock concentration of 10mM.

30

Pramipexole Standard

Dissolved in 100% DMSO to yield a stock concentration of 10mM.

Cyclase Activation Flashplate Assay (NEN SMP004B)

35 Supplied by Perkin-Elmer Life Sciences, Inc

[¹²⁵I]-cyclic Adenosine Monophosphate (cAMP) (NEX 130)

Supplied by Perkin-Elmer Life Sciences, Inc

Specific Equipment*Westbart Microtitre Plate Shaker/Incubator*

Packard Topcount NXT (ECADA compatible programme)

Tecan Genesis

5 Labsystems Multi-drop DW

PROTOCOL TESTING COMPOUND ACTIVITY WITH hD₃CHO CELLS**Compound Dilutions**

10

- Pramipexole is included as a reference standard. A 10-point, semi-log curve is generated every 4 plates. Compound results are normalised to the minimum (0nM pramipexole) and maximum (100nM pramipexole) responses generated by the cells. All test compounds may also be

15

- Test compounds are dissolved in 100% DMSO to yield a stock concentration of 10mM. These are further diluted in 100% DMSO to 1mM via a 10-fold dilution (1000x the final assay concentration required, e.g. 1mM will give a top concentration of 1µM).

20

- Pramipexole is dissolved in 100% DMSO to give a concentration of 10mM. Pramipexole is diluted further to 0.1mM in 100% DMSO via a 100-fold dilution.

- Further dilutions and additions are carried out in 0.4%DMSO/PBS using a suitable Tecan Genesis Protocol, capable of performing serial dilutions at a fold of 3.159 (semi-log unit).

25

TECAN GENESIS DILUTIONS

- 10µL of the test compounds are added to column 1 of a microplate. 240 µL of 0.4% DMSO/PBS is added to this to give a 25-fold dilution (0.04mM). 20 µL of the 0.04mM dilution is transferred to the wells of column 2 where 180µL of 0.4% DMSO/PBS is added, giving a further 10-fold dilution to achieve a 4 x top assay concentration (0.004mM).

30

- Serial dilutions are performed (3.159-fold) to achieve a semi-log dilution series:

35

- **4µM, 1.27µM, 400nM, 127nM, 40nM, 13nM, 4nM, 1.27nM, 0.4nM, 0.1nM**

- 25 µL (in duplicate) of the serial dilutions are transferred to columns 2-11 of the Flashplate (See Appendix). Since the final assay volume is 100µL, the final assay concentrations will be:

40

- **1000µM, 317nM, 100nM, 32nM, 10nM, 3.2nM, 1nM, 0.3nM, 0.1nM, 0.03nM**

- Minimum control (low control) : 25µL 0.4% DMSO/PBS (vehicle) is added to the following wells (column 1 wells E-H and column 2 wells A-D). Cells + forskolin are added later.

45

- Maximum control (high control) : 10mM pramipexole is diluted in PBS via a 250-fold dilution (10µL + 2490µL PBS) to generate 40µM pramipexole.

- 5 40μM pramipexole is further diluted via a 100-fold dilution in 0.4%DMSO/PBS (100μL + 9900μL Vehicle) to generate 400nM (4x assay concentration of the standard pramipexole). 25 μL of 400nM pramipexole is added to the following wells of the Flashplate to yield 100nM pramipexole final; column 1 wells A-D and column 12 wells E-H. Cells + forskolin are added later.

Cyclase-activation Flashplate assay. (NEN SMP004B)

- 10
- As described in the Materials section, forskolin is dissolved in distilled water to achieve a stock concentration of 20mM. This is further diluted to 40μM (4x assay concentration) using PBS. 25μL of 40μM stock is added to all wells using a Multi-drop, giving a final concentration of 10μM. Plates are
- 15 then sealed and incubated at 37°C in a Westbart incubator while cells are harvested.
- Cells are harvested from flasks, which are between 70% - 80% confluent. It is essential that all components added to the cells are warmed to 37°C. 5 mL of CDS is added per T225 flask and incubated at 37°C for 5 minutes before
- 20 being neutralised with 5mL PBS. The cells are then centrifuged at 160g (1000rpm) for 5 minutes. The resultant supernatant is discarded and cells are re-suspended in Stimulation Buffer (warmed to 37°C), to achieve 5×10^5 cells/ml. 50μl of cell suspension is then dispensed into all wells of the Flashplate.

25

 - Plates are immediately incubated at 37°C on a shaking incubator for 15 minutes. The reaction is terminated with 100μl of Detection Mix in all wells (100μL 125 I cAMP: 11 ml Detection buffer per plate).

30

 - Plates are re-sealed and incubated in the dark for 3 hours to allow equilibrium between the anti-cAMP antibody (coating the wells), [125 I]-cAMP tracer and cellular cAMP.
 - Plates are counted on a Packard Topcount NXT using a suitable ECADA compatible protocol (Protocol 75)

RESUSCITATION OF FROZEN AMPOULES

Remove ampoules from liquid nitrogen and allow them to equilibrate for 2 minutes as trapped gas or liquid may cause the ampoule to expand rapidly and explode. They can also be placed at minus 20°C for 2 minutes before thawing.

- 40 Thaw ampoules quickly and completely at 37°C in a water bath.

Transfer cell suspension to a 75cm² flask containing 10mL growth media and incubate for 24h at 37°C, 5% CO₂. After cell attachment (3-6 hours) media is

removed and replaced with fresh media (to remove DMSO). After 24h, if approaching confluency, cells are transferred to a 225cm² flask. If not, the cells are maintained until they are 70%-80% confluent.

5

Cell harvesting and splitting

Cells are split on a Friday to provide cells for assays on Monday and Tuesday. Cells required for the remainder of the week are split on a Monday.

- 10 It is essential **not** to allow the hD₃CHO cells grow beyond 80% confluence, or to create splits >1:20, as this has detrimental effects on their proliferative response and will subsequently effect the cells ability to perform in the assay.

Cells are grown in 225cm² flasks (Jumbos). Every component added to the

- 15 cells must be warmed to 37°C before use.

Cell harvest

- 20 Growth media is removed from flasks and cells are washed with warm PBS (Gibco. 14040-091) and removed.

- 5mL of cell dissociation buffer is added to cells and placed in incubator for approx. 5 minutes.
- 25 • Flasks given a sharp tap to dislodge any remaining cells from the tissue culture plastic.
- 5mL of PBS is added to the cells and used to wash the base and of the flask. Cells are centrifuged for 5 minutes at 160g (1000rpm) to pellet the cells.
- 30 • Supernatant is discarded and 5mL of Stimulation Buffer is used to re-suspend the cells. A trypan blue exclusion assay is carried out to determine the number of viable cells.
- Cells are diluted in Stimulation Buffer to yield a concentration of 5 x 10⁵ cells/ml.
- 35 • To passage to cells the centrifugation step is omitted and the cell suspension is dispensed into new T225 flasks containing 50mL media.

Split ratios

- 40 hD₃CHO are split between 1:5 to 1:10. The culture cannot be continued beyond passage

30 as cell line characteristics are lost with increased passage.

Cryopreservation of cell lines

5

It is essential to create a cell bank of your own cells to resuscitate for further use.

10

- Cells are harvested as described in the previous section. Following the trypan blue exclusion assay, cells are diluted in medium containing 10% DMSO to achieve 2 to 4x10⁶ cells/ml.
- Cells are divided into 1ml aliquots and immediately frozen down gradually, in a 'Mr Frosty', (containing fresh IPA) at -80°C prior to being transferred to a gaseous-phase liquid- nitrogen storage vessel. (Cells may be stored in the 'Mr Frosty' for up to 2 days).

15

It is advisable to test the cell viability by thawing one ampoule after freezing. Viabilities below 70 % may cause problems on recovery due to low cell numbers and the presence of debris.

20

DATA ANALYSIS

The data is analysed using ECADA.

25

% Normalisation (in relation to pramipexole) is generated for all compounds via the following formulae:

$$\% \text{ Normalisation} = (X - B_0) / (\text{Max} - B_0) \times 100$$

where,

30

x = Average net counts for a given concentration of test compound,
Bo = Average net counts of minimum control (0nM of Pramipexole) and,
Max = Average net counts given of maximum control (100nM Pramipexole)

35

Curves can be generated by plotting % normalisation (y) versus concentration of agonist in nM (x). Data is fitted using non-linear regression with the slope constrained to 1. From this, an EC50 and %Emax for the test compound are determined.

40

Assay Plate Layout (10-point EC50):

	1	2	3	4	5	6	7	8	9	10	11	12
A	MAX	C1										MIN
B	MAX	C1										MIN
C	MAX	C2										MIN
D	MAX	C2										MIN
E	MIN	C3										MAX
F	MIN	C3										MAX
G	MIN	C4										MAX
H	MIN	C4										MAX

Column 1: Wells A-D = MAX: High Controls (cells + forskolin + 100nM pramipexole)

Wells E-H = MIN: Low Controls (cells + forskolin + vehicle)

- 5 Column 12: Wells A-D = MIN: Low Controls (cells + forskolin + vehicle)
Wells E- H =MAX: High Controls (cells + forskolin + 100nM pramipexole)

- 10 Columns 2-11: 10-point serial dilutions (in duplicate) of test-compounds.
Decreasing concentrations from columns 2 to 11 (1000nM to 0.03nM).
Pramipexole replaces C1 in first plate.

Inhibition Via Dopamine D2 Receptors of Forskolin Stimulated Adenylate Cyclase Activity

MATERIALS

Cell culture media:

HD2 GH4C1/hD _{2L} Medium
Hams F-12 (Sigma N6013)
2mM L-Glutamine (Sigma G7513)
10% FBS (Gibco 10106-169)
700µg/ml Geneticin (Gibco 10131-019)

GH4C1/hD_{2L} are rat pituitary cells expressing the human dopamine D2_{long} receptor.

Media is made up fresh every week as below and filtered through a 0.22µM filter before use. Media is stored at 4°C and warmed to 37°C for addition to the cells.

Cell Dissociation Solution (CDS): (Sigma C-5914)
5mL used to harvest cells from 225cm² flask

Phosphate Buffered Salin (PBS): (Gibco. 14040-091)

Trypan Blue: (Sigma T8154)

5 **Forskolin** (Calbiochem 344273)

Dissolved to a concentration of 20mM in distilled water. (This stock is stored at +4°C).

4x assay stock of 20µM made by carrying out a 1000-fold dilution in PBS buffer. 25µl of the 20µM stock is added to a final assay volume of 100µl, giving a final

10 assay concentration of 5µM.

Test compounds

Dissolved to a concentration of 10mM in 100% DMSO

15 **Pramipexole Standard**

Dissolved in 100% DMSO to yield a final stock concentration of 10mM.

Cyclase Activation Flashplate Assay (NEN SMP004B)

Supplied by Perkin-Elmer Life Sciences, Inc

20

[¹²⁵I]-cyclic Adenosine Monophosphate (cAMP) (NEX 130)

Supplied by Perkin-Elmer Life Sciences, Inc

Specific Equipment

25 ***Westbart Microtitre Plate Shaker/Incubator***

Packard Topcount NXT (ECADA compatible programme)

Tecan Genesis

Labsystems Multi-drop DW

30 **PROTOCOLS**

Compound Dilutions

- 35
- Pramipexole is included as a reference standard. A 10-point, semi-log curve is generated every 4 plates. Compound responses are normalised to the minimum (0nM pramipexole) and maximum (1000nM Pramipexole) responses generated by the cells. All test compounds may also be tested via a 10-point (semi-log) curve.
- 40
- Test compounds are dissolved in 100% DMSO to yield a stock concentration of 10mM, (1000x the final assay concentration required, e.g. 10mM will give a top concentration of 10000nM).
 - Pramipexole is dissolved in 100% DMSO to give a concentration of 10mM. Pramipexole is diluted further to 1mM in 100% DMSO via a 10-fold dilution.

- Further dilutions and additions are carried out in 0.4 %DMSO/PBS using a suitable Tecan Genesis Protocol which is capable of performing serial dilutions at a fold of 3.159 (semi-log unit).

5 TECAN GENESIS DILUTIONS

- 10µL of the test compounds are added to column 1 of a microplate. 240µL of 0.4% DMSO/PBS is added to this to give a 25-fold dilution (0.4mM). 20µL of the 0.4mM dilution is transferred to wells of column 2 where 180uL of 0.4% DMSO/PBS is added, giving a further 10-fold dilution to achieve a 4x top assay concentration (0.04mM).
- Serial dilutions are performed (3.159-fold) to achieve a semi-log dilution series:
40µM, 12.7µM, 4µM, 1.27µM, 400nM, 130nM, 40nM, 13nM, 4nM, 1.3nM
- 25µL (in duplicate) of the serial dilutions are transferred to columns 2-11 of the Flashplate (See Appendix). Since the final assay volume is 100µL, the final assay concentrations will be:
10,000uM, 3170nM, 1000nM, 320nM, 100nM, 32nM, 10nM, 3nM, 1nM, 0.3nM
- Minimum control (low control): 25µL of 0.4% DMSO/PBS (vehicle) is added to the following wells (column 1 wells E-H and column 2 wells A-D). Cells and forskolin are added later.
- Maximum control (high control) : 10mM pramipexole is diluted in PBS via a 250-fold dilution (10µL + 2490µL PBS) to generate 40µM pramipexole. 40µM pramipexole is further diluted via a 10-fold dilution in 0.4%DMSO/PBS (100µL + 990µL Vehicle) to generate 4000nM (4x assay concentration of the standard pramipexole). 25µL of 4000nM pramipexole is added to the following wells of the Flashplate to yield 1000nM pramipexole final; column 1 wells A-D and column 12 wells E-H. Cells + forskolin are added later.

Cyclase-activation Flashplate assay. (NEN SMP004B)

- As described in the Materials section, forskolin is dissolved in distilled water to achieve a stock concentration of 20mM. This is further diluted to 20µM (4x assay concentration) using PBS. 25µL is added to all wells using a Multi-drop, giving a final concentration of 5µM. Plates are then sealed and incubated at 37°C in a Westbart incubator while cells are harvested.
- Cells are harvested from flasks which are between 70% - 80% confluent. It is essential that all components added to the cells are warmed to 37°C. 5mL of CDS is added per 225cm² flask, and incubated at 37°C for 5 minutes before being neutralised with 5mL PBS. The cells are then centrifuged at 160g (1000rpm) for 5 minutes. The resultant supernatant is discarded and cells are re-suspended in Stimulation Buffer (warmed to

- 37°C), to achieve 1×10^5 cells/ml. 50µl of cell suspension is then dispensed into all wells of the Flashplate.
- Plates are immediately incubated at 37°C on a shaking incubator for 15 minutes. The reaction is terminated with 100µl of Detection Mix in all wells (100µL 125 I cAMP: 11 ml Detection buffer plate).
 - Plates are re-sealed and incubated in the dark for 3 hours to allow equilibrium between the anti-cAMP antibody (coating the wells), [125 I]-cAMP tracer and cellular cAMP.
 - Plates are counted on a Packard Topcount NXT using a suitable ECADA compatible protocol (Protocol 75)

RESUSCITATION OF FROZEN AMPOULES

- Remove ampoules from liquid nitrogen and allow them to equilibrate for 2 minutes as trapped gas or liquid may cause the ampoule to expand rapidly and explode. They can also be placed at minus 20°C for 2 minutes before thawing.

Thaw ampoules quickly and completely at 37°C in a water bath.

- Transfer cell suspension to a 75cm² flask containing 10mL growth media and incubate for 24h at 37°C, 5% CO₂. After cell attachment (3-6 hours) media is removed and replaced with fresh media (to remove DMSO). After 24h, if approaching confluency, cells are transferred to a 225cm² flask. If not, the cells are maintained until they are 60% confluent.

Cell harvesting and splitting

- Cells are split on a Friday to provide cells for assays on Monday and Tuesday. Cells required for the remainder of the week are split on a Monday. It is essential **not** to allow the cells grow beyond 60% confluence as this has detrimental effects on their proliferative response and will subsequently effect the cells ability to perform in the assay.
- Cells are grown in 225cm² flasks (Jumbos). Every component added to the cells must be warmed to 37°C before use.

C II harvest

Growth media is removed from flasks and cells are washed with warm PBS (Gibco. 14040-091) and removed.

- 5 • 5mL of cell dissociation buffer is added to cells and placed in incubator for approx. 5 minutes.
- Flasks given a sharp tap to dislodge any remaining cells from the tissue culture plastic.
- 5mL of PBS is added to the cells and used to wash the base and of the flask. Cells are centrifuged for 5 minutes at 160g (1000rpm) to pellet the cells.
- 10 • Supernatant is discarded and 5mL of Stimulation Buffer is used to re-suspend the cells. A trypan blue exclusion assay is carried out to determine the number of viable cells.
- Cells are diluted in Stimulation Buffer to yield a concentration of 1×10^5 cells/ml.
- 15 • To passage to cells the centrifugation step is omitted and the cell suspension is dispensed into new T225 flasks containing 50mL media.

Split ratios

- 20 GH4C1/D2 are split between 1:3 to 1:5.

Cryopreservation of cell lines

- 25 It is essential to create a cell bank of your own cells to resuscitate for further use.
- 30 • Cells are harvested as described in the previous section. Following the trypan blue exclusion assay, cells are diluted in medium containing 10% DMSO to achieve 2 to 4×10^6 cells/ml.
 - Cells are divided into 1ml aliquots and immediately frozen down gradually, in a 'Mr Frosty', (containing fresh IPA) at -80°C prior to being transferred to a gaseous-phase liquid- nitrogen storage vessel. (Cells may be stored in the 'Mr Frosty' for up to 2 days).
- 35 It is advisable to test the cell viability by thawing one ampoule after freezing. Viabilities below 70 % may cause problems on recovery due to low cell numbers and the presence of debris.

40 DATA ANALYSIS

The data is analysed using ECADA.

% Normalisation (in relation to pramipexole) is generated for all compounds via the following formulae:

$$\% \text{ Normalisation} = (X - B_0) / (\text{Max} - B_0) \times 100$$

5 where,

x = Average net counts for a given concentration of test compound,

Bo = Average net counts of minimum control (0nM of Pramipexole) and,

Max = Average net counts given of maximum control (100nM Pramipexole)

10 Curves can be generated by plotting % normalisation (y) versus concentration of agonist in nM (x). Data is fitted using non-linear regression with the slope constrained to 1. From this, an EC50 and %Emax for the test compound are determined.

15 **Assay Plate Layout (10-point EC50):**

	1	2	3	4	5	6	7	8	9	10	11	12
A	MAX	C1										MIN
B	MAX	C1										MIN
C	MAX	C2										MIN
D	MAX	C2										MIN
E	MIN	C3										MAX
F	MIN	C3										MAX
G	MIN	C4										MAX
H	MIN	C4										MAX

Column 1: Wells A-D = MAX: High Controls (cells + forskolin + 100nM pramipexole)

Wells E-H = MIN: Low Controls (cells + forskolin + vehicle)

20

Column 12: Wells A-D = MIN: Low Controls (cells + forskolin + vehicle)

Wells E- H =MAX: High Controls (cells + forskolin + 100nM pramipexole)

25 Columns 2-11: 10-point serial dilutions (in duplicate) of test-compounds. Decreasing concentrations from columns 2 to 11 (1000nM to 0.03nM). Pramipexole replaces C1 in first plate.

Using the assay described above, the compounds of the present invention all
 30 exhibit a functional potency at D3 receptor expressed as an EC50, lower than 1000nM and a 10 fold selectivity for D3 over D2.

Compound of example 8 has a functional potency at D3 receptor expressed as an EC50, of 7.6nM and 1315.8 fold selectivity for D3 over D2. Selectivity is

calculated as the D2 EC50 value divided by the D3 EC50 value. Where the value of the D2 EC50 was >10000, a figure of 10000 was used in the calculation.

- 5 It is to be appreciated that all references herein to treatment include curative, palliative and prophylactic treatment.

Suitable auxiliary active agents for use in the combinations of the present invention include:

10

- 1) Naturally occurring or synthetic prostaglandins or esters thereof. Suitable prostaglandins for use herein include compounds such as alprostadil, prostaglandin E₁, prostaglandin E₀, 13, 14 - dihydroprosta glandin E₁, prostaglandin E₂, eprostinol, natural synthetic and semi-synthetic
15 prostaglandins and derivatives thereof including those described in WO-00033825 and/or US 6,037,346 issued on 14th March 2000 all incorporated herein by reference, PGE₀, PGE₁, PGA₁, PGB₁, PGF₁ α, 19-hydroxy PGA₁, 19-hydroxy - PGB₁, PGE₂, PGB₂, 19-hydroxy-PGA₂, 19-hydroxy-PGB₂, PGE₃α, carboprost tromethamine dinoprost, tromethamine, dinoprostone,
20 lipo prost, gemeprost, metenoprost, sulprostune, tiaprost and moxisylate;

- 2) α - adrenergic receptor antagonist compounds also known as α - adrenoceptors or α-receptors or α-blockers. Suitable compounds for use herein include: the α-adrenergic receptor blockers as described in PCT application WO99/30697 published on 14th June 1998, the disclosures of
25 which relating to α-adrenergic receptors are incorporated herein by reference and include, selective α₁-adrenoceptor or α₂-adrenoceptor blockers and non-selective adrenoceptor blockers, suitable α₁-adrenoceptor blockers include: phentolamine, phentolamine mesylate, trazodone, alfuzosin, indoramin, naftopidil, tamsulosin, dapiprazole,
30 phenoxybenzamine, idazoxan, efaraxan, yohimbine, rauwolfia alkaloids, Recordati 15/2739, SNAP 1069, SNAP 5089, RS17053, SL 89.0591,

- doxazosin, terazosin, abanoquil and prazosin; α_2 -blocker blockers from US 6,037,346 [14th March 2000] dibenarnine, tolazoline, trimazosin and dibenarnine; α -adrenergic receptors as described in US patents: 4,188,390; 4,026,894; 3,511,836; 4,315,007; 3,527,761; 3,997,666; 2,503,059; 5 4,703,063; 3,381,009; 4,252,721 and 2,599,000 each of which is incorporated herein by reference; α_2 -Adrenoceptor blockers include: clonidine, papaverine, papaverine hydrochloride, optionally in the presence of a cariotonic agent such as pirxamine;
- 10 3) NO-donor (NO-agonist) compounds. Suitable NO-donor compounds for use herein include organic nitrates, such as mono- di or tri-nitrates or organic nitrate esters including glyceryl trinitrate (also known as nitroglycerin), isosorbide 5-mononitrate, isosorbide dinitrate, pentaerythritol tetranitrate, erythrityl tetranitrate, sodium nitroprusside (SNP), 3-morpholinolonylnonimine
- 15 molsidomine, S-nitroso- N-acetyl penicillamine (SNAP) S-nitroso-N-glutathione (SNO-GLU), N-hydroxy - L-arginine, amyl nitrate, linsidomine, linsidomine chlorohydrate, (SIN-1) S-nitroso - N-cysteine, diazenium diolates, (NONOates), 1,5-pentanedinitrate, L-arginine, ginseng, zizphi fructus, molsidomine, Re - 2047, nitrosylated maxisylate derivatives such as
- 20 NMI-678-11 and NMI-937 as described in published PCT application WO 0012075;
- 4) Potassium channel openers or modulators. Suitable potassium channel openers/modulators for use herein include nicorandil, cromokalim,
- 25 levcromakalim, lemakalim, pinacidil, cliazoxide, minoxidil, charybdotoxin, glyburide, 4-aminopyridine, BaCl_2 ;
- 5) Vasodilator agents. Suitable vasodilator agents for use herein include nimodipine, pinacidil, cycloandelate, isoxsuprine, chlorpromazine, halo
- 30 peridol, Rec 15/2739, trazodone;
- 6) Thromboxane A₂ agonists;

7) CNS active agents;

8) Ergot alkaloids; Suitable ergot alkaloids are described in US patent
5 6,037,346 issued on 14th March 2000 and include acetergamine,
brazergoline, bromerguride, cianergoline, delorgotril, disulergine,
ergonovine maleate, ergotamine tartrate, etisulergine, lergotril, lysergide,
mesulergine, metergoline, metergotamine, nicergoline, pergolide,
propisergide, proterguride and terguride;

10

9) Compounds which modulate the action of natruretic factors in particular
atrial naturetic factor (also known as atrial naturetic peptide), B type and C
type naturetic factors such as inhibitors or neutral endopeptidase;

15 10) Compounds which inhibit angiotensin-converting enzyme such as enapril,
and combined inhibitors of angiotensin-converting enzyme and neutral
endopeptidase such as omapatrilat.

11) Angiotensin receptor antagonists such as losartan;

20

12) Substrates for NO-synthase, such as L-arginine;

13) Calcium channel blockers such as amlodipine;

25 14) Antagonists of endothelin receptors and inhibitors or endothelin-converting
enzyme;

15) Cholesterol lowering agents such as statins (e.g. atorvastatin/ Lipitor- trade
mark) and fibrates;

30

16) Antiplatelet and antithrombotic agents, e.g. tPA, uPA, warfarin, hirudin and
other thrombin inhibitors, heparin, thromboplastin activating factor inhibitors;

- 17) Insulin sensitising agents such as rezulin and hypoglycaemic agents such as glipizide;
- 5 18) L-DOPA or carbidopa;
- 19) Acetylcholinesterase inhibitors such as donezipil;
- 20) Steroidal or non-steroidal anti-inflammatory agents;
- 10 21) Estrogen receptor modulators and/or estrogen agonists and/or estrogen antagonists, preferably raloxifene or lasofoxifene, (-)-cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-5,6,7,8-tetrahydronaphthalene-2-ol and pharmaceutically acceptable salts thereof the preparation of which is
- 15 detailed in WO 96/21656;
- 23) A PDE inhibitor, more particularly a PDE 2, 3, 4, 5, 7 or 8 inhibitor, preferably PDE2 or PDE5 inhibitor and most preferably a PDE5 inhibitor (see hereinafter), said inhibitors preferably having an IC₅₀ against the
- 20 respective enzyme of less than 100nM (with the proviso that PDE 3 and 4 inhibitors are only administered topically or by injection to the penis);
- 22) Vasoactive intestinal protein (VIP), VIP mimetic, VIP analogue, more particularly mediated by one or more of the VIP receptor subtypes
- 25 VPAC1, VPAC or PACAP (pituitary adenylate cyclase activating peptide), one or more of a VIP receptor agonist or a VIP analogue (e.g. Ro-125-1553) or a VIP fragment, one or more of a α -adrenoceptor antagonist with VIP combination (e.g. Invicorp, Aviptadil);
- 30 23) A melanocortin receptor agonist or modulator or melanocortin enhance, such as melanotan II, PT-14, PT-141 or compounds claimed in WO-

09964002, WO-00074679, WO-09955679, WO-00105401, WO-00058361, WO-00114879, WO-00113112, WO-09954358;

- 24) A serotonin receptor agonist, antagonist or modulator, more particularly
5 agonists, antagonists or modulators for 5HT1A (including VML 670),
5HT2A, 5HT2C, 5HT3 and/or 5HT6 receptors, including those described
in WO-09902159, WO-00002550 and/or WO-00028993;
- 25) A testosterone replacement agent (including dehydroandrostendione),
10 testosternone (Tostrelle), dihydrotestosterone or a testosterone implant;
- 26) Estrogen, estrogen and medroxyprogesterone or medroxyprogesterone
acetate (MPA) (i.e. as a combination), or estrogen and methyl
15 testosterone hormone replacement therapy agent (e.g. HRT especially
Premarin, Cenestin, Oestrofeminal, Equin, Estrace, Estrofem, Elleste
Solo, Estring, Eastraderm TTS, Eastraderm Matrix, Dermestril,
Premphase, Preempro, Prempak, Premique, Estratest, Estratest HS,
Tibolone);
- 20 27) A modulator of transporters for noradrenaline, dopamine and/or
serotonin, such as bupropion, GW-320659;
- 28) A purinergic receptor agonist and/or modulator;
- 25 29) A neurokinin (NK) receptor antagonist, including those described in WO-
09964008;
- 30) An opioid receptor agonist, antagonist or modulator, preferably agonists
for the ORL-1 receptor;
- 30 31) An agonist or modulator for oxytocin/vasopressin receptors, preferably a
selective oxytocin agonist or modulator;

32)Modulators of cannabinoid receptors;

- 33) A SEP inhibitor (SEPi), for instance a SEPi having an IC_{50} at less than
5 100 nanomolar, more preferably, at less than 50 nanomolar.

Preferably, the SEP inhibitors according to the present invention have
greater than 30-fold, more preferably greater than 50-fold selectivity for
SEP over neutral endopeptidase NEP EC 3.4.24.11 and angiotensin
10 converting enzyme (ACE). Preferably the SEPi also has a greater than
100-fold selectivity over endothelin converting enzyme (ECE).

By cross reference herein to compounds contained in patents and patent
applications which can be used in accordance with invention, we mean the
15 therapeutically active compounds as defined in the claims (in particular of claim
1) and the specific examples (all of which is incorporated herein by reference).

If a combination of active agents is administered, then they may be
administered simultaneously, separately or sequentially.

20

Auxiliary Agents - PDE5 Inhibitors

The suitability of any particular cGMP PDE5 inhibitor can be readily determined
by evaluation of its potency and selectivity using literature methods followed by
25 evaluation of its toxicity, absorption, metabolism, pharmacokinetics, etc in
accordance with standard pharmaceutical practice.

IC_{50} values for the cGMP PDE5 inhibitors may be determined using the PDE5
assay (see hereinbelow).

30

Preferably the cGMP PDE5 inhibitors used in the pharmaceutical combinations
according to the present invention are selective for the PDE5 enzyme.

Preferably (when used orally) they are selective over PDE3, more preferably over PDE3 and PDE4. Preferably (when oral), the cGMP PDE5 inhibitors of the invention have a selectivity ratio greater than 100 more preferably greater than 300, over PDE3 and more preferably over PDE3 and PDE4.

5

Selectivity ratios may readily be determined by the skilled person. IC50 values for the PDE3 and PDE4 enzyme may be determined using established literature methodology, see S A Ballard *et al*, Journal of Urology, 1998, vol. 159, pages 2164-2171 and as detailed herein after.

10

Suitable cGMP PDE5 inhibitors for the use according to the present invention include:

the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in EP-A-0463756; the
15 pyrazolo [4,3-d]pyrimidin-7-ones disclosed in EP-A-0526004; the
pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international
patent application WO 93/06104; the isomeric pyrazolo [3,4-d]pyrimidin-
4-ones disclosed in published international patent application WO
93/07149; the quinazolin-4-ones disclosed in published international
20 patent application WO 93/12095; the pyrido [3,2-d]pyrimidin-4-ones
disclosed in published international patent application WO 94/05661; the
purin-6-ones disclosed in published international patent application WO
94/00453; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published
international patent application WO 98/49166; the pyrazolo [4,3-
25 d]pyrimidin-7-ones disclosed in published international patent application
WO 99/54333; the pyrazolo [4,3-d]pyrimidin-4-ones disclosed in EP-A-
0995751; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published
international patent application WO 00/24745; the pyrazolo [4,3-
d]pyrimidin-4-ones disclosed in EP-A-0995750; the compounds
30 disclosed in published international application WO95/19978; the
compounds disclosed in published international application WO
99/24433 and the compounds disclosed in published international

application WO 93/07124. The pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international application WO 01/27112; the pyrazolo [4,3-d]pyrimidin-7-ones disclosed in published international application WO 01/27113; the compounds disclosed in EP-A-1092718
5 and the compounds disclosed in EP-A-1092719.

Further suitable PDE5 inhibitors for the use according to the present invention include:

10 5-[2-ethoxy-5-(4-methyl-1-piperazinylsulphonyl)phenyl]-1-methyl-3-n-propyl-1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (sildenafil) also known as 1-[[3-(6,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo[4,3-d]pyrimidin-5-yl)-4-ethoxyphenyl]sulphonyl]-4-methylpiperazine (see EP-A-0463756); 5-(2-ethoxy-5-morpholinoacetylphenyl)-1-methyl-3-n-propyl-
15 1,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see EP-A-0526004); 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-n-propoxyphenyl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO98/49166); 3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxyethoxy)pyridin-3-yl]-2-(pyridin-2-yl)methyl-2,6-dihydro-7H-
20 pyrazolo[4,3-d]pyrimidin-7-one (see WO99/54333); (+)-3-ethyl-5-[5-(4-ethylpiperazin-1-ylsulphonyl)-2-(2-methoxy-1(R)-methylethoxy)pyridin-3-yl]-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, also known as 3-ethyl-5-{5-[4-ethylpiperazin-1-ylsulphonyl]-2-[(1R)-2-methoxy-1-methylethyl]oxy}pyridin-3-yl}-2-methyl-2,6-dihydro-7H-pyrazolo[4,3-d]
25 pyrimidin-7-one (see WO99/54333); 5-[2-ethoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-[2-methoxyethyl]-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one, also known as 1-{6-ethoxy-5-[3-ethyl-6,7-dihydro-2-(2-methoxyethyl)-7-oxo-2H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-pyridylsulphonyl}-4-ethylpiperazine (see WO 01/27113, Example 8); 5-[2-
30 *iso*-Butoxy-5-(4-ethylpiperazin-1-ylsulphonyl)pyridin-3-yl]-3-ethyl-2-(1-methylpiperidin-4-yl)-2,6-dihydro-7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27113, Example 15); 5-[2-Ethoxy-5-(4-ethylpiperazin-1-

ylsulphonyl)pyridin-3-yl]-3-ethyl-2-phenyl-2,6-dihydro-7H-pyrazolo[4,3-
 d]pyrimidin-7-one (see WO 01/27113, Example 66); 5-(5-Acetyl-2-
 propoxy-3-pyridinyl)-3-ethyl-2-(1-isopropyl-3-azetidiny)-2,6-dihydro-7H-
 pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27112, Example 124); 5-(5-
 5 Acetyl-2-butoxy-3-pyridinyl)-3-ethyl-2-(1-ethyl-3-azetidiny)-2,6-dihydro-
 7H-pyrazolo[4,3-d]pyrimidin-7-one (see WO 01/27112, Example 132);
 (6R,12aR)-2,3,6,7,12,12a-hexahydro-2-methyl-6-(3,4-
 methylenedioxyphenyl) -pyrazino[2',1':6,1]pyrido[3,4-b]indole-1,4-dione
 (IC-351), i.e. the compound of examples 78 and 95 of published
 10 international application WO95/19978, as well as the compound of
 examples 1, 3, 7 and 8; 2-[2-ethoxy-5-(4-ethyl-piperazin-1-yl)-1-
 sulphonyl]-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-
 one (vardenafil) also known as 1-[[3-(3,4-dihydro-5-methyl-4-oxo-7-
 propylimidazo[5,1-f]-as-triazin-2-yl)-4-ethoxyphenyl]sulphonyl]-4-
 15 ethylpiperazine, i.e. the compound of examples 20, 19, 337 and 336 of
 published international application WO99/24433; and the compound of
 example 11 of published international application WO93/07124 (EISAI);
 and compounds 3 and 14 from Rotella D P, *J. Med. Chem.*, 2000, 43, ...
 1257.

20

Still other suitable PDE5 inhibitors include:

4-bromo-5-(pyridylmethylamino)-6-[3-(4-chlorophenyl)-propoxy]-
 3(2H)pyridazinone; 1-[4-[(1,3-benzodioxol-5-ylmethyl)amino]-6-chloro-2-
 25 quinoxoliny]-4-piperidine-carboxylic acid, monosodium salt; (+)-cis-
 5,6a,7,9,9a-hexahydro-2-[4-(trifluoromethyl)-phenylmethyl-5-methyl-
 cyclopent-4,5]imidazo[2,1-b]purin-4(3H)one; furazlocillin; cis-2-hexyl-5-methyl-
 3,4,5,6a,7,8,9,9a- octahydrocyclopent[4,5]-imidazo[2,1-b]purin-4-one; 3-acetyl-
 1-(2-chlorobenzyl)-2-propylindole-6- carboxylate; 3-acetyl-1-(2-chlorobenzyl)-2-
 30 propylindole-6-carboxylate; 4-bromo-5-(3-pyridylmethylamino)-6-(3-(4-
 chlorophenyl) propoxy)-3- (2H)pyridazinone; 1-methyl-5(5-morpholinoacetyl-2-n-
 propoxyphenyl)-3-n-propyl-1,6-dihydro- 7H-pyrazolo(4,3-d)pyrimidin-7-one; 1-
 [4-[(1,3-benzodioxol-5-ylmethyl)arnino]-6-chloro-2- quinazoliny]-4-

piperidinecarboxylic acid, monosodium salt; Pharmaprojects No. 4516 (Glaxo Wellcome); Pharmaprojects No. 5051 (Bayer); Pharmaprojects No. 5064 (Kyowa Hakko; see WO 96/26940); Pharmaprojects No. 5069 (Schering Plough); GF-196960 (Glaxo Wellcome); E-8010 and E-4010 (Eisai); Bay-38-3045 & 38-9456 (Bayer) and Sch-51866.

The compounds of the formula (I) can be administered alone but will generally be administered in admixture with a suitable pharmaceutical excipient, diluent or carrier selected with regard to the intended route of administration and standard pharmaceutical practice.

Accordingly the present invention provides for a composition comprising a compound of formula (I), (Ia) or (Ib) and a pharmaceutically acceptable diluent or carrier.

For example, the compounds of the formula (I), (Ia) or (Ib) can be administered orally, buccally or sublingually in the form of tablets, capsules, ovules, elixirs, solutions or suspensions, which may contain flavouring or colouring agents, for immediate-, delayed-, modified-, sustained-, pulsed- or controlled-release applications.

Such tablets may contain excipients such as microcrystalline cellulose, lactose, sodium citrate, calcium carbonate, dibasic calcium phosphate and glycine, disintegrants such as starch (preferably corn, potato or tapioca starch), sodium starch glycollate, croscarmellose sodium and certain complex silicates, and granulation binders such as polyvinylpyrrolidone, hydroxypropylmethylcellulose (HPMC), hydroxypropylcellulose (HPC), sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, stearic acid, glyceryl behenate and talc may be included.

Solid compositions of a similar type may also be employed as fillers in gelatin capsules. Preferred excipients in this regard include lactose, starch, a

cellulose, milk sugar or high molecular weight polyethylene glycols. For aqueous suspensions and/or elixirs, the compounds of the formula (I), (Ia) or (Ib) may be combined with various sweetening or flavouring agents, colouring matter or dyes, with emulsifying and/or suspending agents and with diluents
5 such as water, ethanol, propylene glycol and glycerin, and combinations thereof.

The compounds of the formula (I), (Ia) or (Ib) can also be administered parenterally, for example, intravenously, intra-arterially, intraperitoneally,
10 intrathecally, intraventricularly, intraurethrally, intrasternally, intracranially, intramuscularly or subcutaneously, or they may be administered by infusion techniques. For such parenteral administration they are best used in the form of a sterile aqueous solution which may contain other substances, for example, enough salts or glucose to make the solution isotonic with blood. The aqueous
15 solutions should be suitably buffered (preferably to a pH of from 3 to 9), if necessary. The preparation of suitable parenteral formulations under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art.

20 The compounds of formula (I), (Ia) or (Ib) can also be administered intranasally or by inhalation, typically in the form of a dry powder (either alone, as a mixture, for example, in a dry blend with lactose, or as a mixed component particle, for example, mixed with phospholipids) from a dry powder inhaler or as an aerosol spray from a pressurised container, pump, spray, atomiser (preferably an
25 atomiser using electrohydrodynamics to produce a fine mist), or nebuliser, with or without the use of a suitable propellant, such as dichlorofluoromethane.

The pressurised container, pump, spray, atomizer, or nebuliser contains a solution or suspension of the active compound comprising, for example,
30 ethanol (optionally, aqueous ethanol) or a suitable alternative agent for dispersing, solubilising, or extending release of the active, the propellant(s) as

solvent and an optional surfactant, such as sorbitan trioleate or an oligolactic acid.

- Prior to use in a dry powder or suspension formulation, the drug product is
- 5 micronised to a size suitable for delivery by inhalation (typically less than 5 microns). This may be achieved by any appropriate comminuting method, such as spiral jet milling, fluid bed jet milling, supercritical fluid processing to form nanoparticles, high pressure homogenisation, or spray drying.
- 10 A suitable solution formulation for use in an atomiser using electrohydrodynamics to produce a fine mist may contain from 1µg to 10mg of the compound of the invention per actuation and the actuation volume may vary from 1µl to 100µl. A typical formulation may comprise a compound of formula (I), (Ia) or (Ib), propylene glycol, sterile water, ethanol and sodium chloride.
- 15 Alternative solvents which may be used instead of propylene glycol include glycerol and polyethylene glycol.

- Capsules, blisters and cartridges (made, for example, from gelatin or HPMC) for use in an inhaler or insufflator may be formulated to contain a powder mix of
- 20 the compound of the invention, a suitable powder base such as lactose or starch and a performance modifier such as *l*-leucine, mannitol, or magnesium stearate.

- Formulations for inhaled/intranasal administration may be formulated to be
- 25 immediate and/or modified release.

- Alternatively, the compounds of the formula (I), (Ia) or (Ib) can be administered in the form of a suppository or pessary, or they may be applied topically in the form of a gel, hydrogel, lotion, solution, cream, ointment or dusting powder.
- 30 The compounds of the formula (I), (Ia) or (Ib) may also be dermally or transdermally administered, for example, by the use of a skin patch. They may also be administered by the pulmonary or rectal routes.

They may also be administered by the ocular route. For ophthalmic use, the compounds can be formulated as micronised suspensions in isotonic, pH adjusted, sterile saline, or, preferably, as solutions in isotonic, pH adjusted, sterile saline, optionally in combination with a preservative such as a benzylalkonium chloride. Alternatively, they may be formulated in an ointment such as petrolatum.

For application topically to the skin, the compounds of the formula (I), (Ia) or (Ib) can be formulated as a suitable ointment containing the active compound suspended or dissolved in, for example, a mixture with one or more of the following: mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene polyoxypropylene compound, emulsifying wax and water. Alternatively, they can be formulated as a suitable lotion or cream, suspended or dissolved in, for example, a mixture of one or more of the following: mineral oil, sorbitan monostearate, a polyethylene glycol, liquid paraffin, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

The compounds of the formula (I), (Ia) or (Ib) may also be used in combination with a cyclodextrin. Cyclodextrins are known to form inclusion and non-inclusion complexes with drug molecules. Formation of a drug-cyclodextrin complex may modify the solubility, dissolution rate, bioavailability and/or stability property of a drug molecule. Drug-cyclodextrin complexes are generally useful for most dosage forms and administration routes. As an alternative to direct complexation with the drug the cyclodextrin may be used as an auxiliary additive, e.g. as a carrier, diluent or solubiliser. Alpha-, beta- and gamma-cyclodextrins are most commonly used and suitable examples are described in WO-A-91/11172, WO-A-94/02518 and WO-A-98/55148.

The present invention is further exemplified by the following, non-limiting examples:

The invention is illustrated by the following non-limiting examples in which the following abbreviations and definitions are used:

α_D	optical rotation at 587nm.
Arbacel®	filter agent
b	broad
Boc	<i>tert</i> -butoxycarbonyl
CDCl ₃	chloroform-d1
CD ₃ OD	methanol-d4
δ	chemical shift
d	doublet
dd	double doublet
DCM	dichloromethane
DMF	<i>N,N</i> -dimethylformamide
DMSO	dimethylsulfoxide
h	hours
HCl	hydrogen chloride
LRMS	low resolution mass spectrum
m	multiplet
m/z	mass spectrum peak
min	minutes
Mpt	melting point
NaOH	sodium hydroxide
NMR	nuclear magnetic resonance
q	quartet
s	singlet
t	triplet
Tf	trifluoromethanesulfonyl
TFA	trifluoroacetic acid
THF	tetrahydrofuran


TLC thin layer chromatography

Melting points were determined using a Perkin Elmer DSC7 at a heating rate of 20°C/minute).

- 5 X-RAY DIFFRACTION DATA WERE RECORDED AT ROOM TEMPERATURE USING A BRUKER AXS SMART-APEX CCD AREA-DETECTOR DIFFRACTOMETER (MO K α RADIATION). INTENSITIES WERE INTEGRATED FROM SEVERAL SERIES OF EXPOSURES. EACH EXPOSURE COVERED 0.3° IN ω , WITH AN EXPOSURE TIME OF 60 S AND
- 10 THE TOTAL DATA SET WAS MORE THAN A SPHERE.

Example 1


2-Amino-1-(3-methoxyphenyl)ethanol




- 15 3-Methoxybenzaldehyde (27.2g, 0.2mol) in THF (150ml) was added to a stirred solution of 3N HCl (aq) (150ml, 0.3mol) and sodium sulphite (37.8g, 0.3mol) at room temperature. After 10 minutes potassium cyanide (19.53g, 0.3mol) was added, portion wise, and the reaction mixture was then stirred for 30 minutes. Diethyl ether (800ml) and water (300ml) were added and subsequent layers
- 20 partitioned. Aqueous re-extracted with diethyl ether (500ml) the organics combined, dried over anhydrous magnesium sulphate, filtered then concentrated *in vacuo* to give the cyanohydrin intermediate as a colourless oil, (35.57g, 0.22mol, >100%). Borane-tetrahydrofuran complex (1M in THF) (400ml, 0.4mol) was then cautiously added to the cyanohydrin in THF (100ml).
- 25 Once effervescence had ceased, stirring was continued at reflux for 1.5 hours under an atmosphere of nitrogen. The reaction mixture was cooled then quenched with methanol (40ml) before concentrating *in vacuo* to give a

colourless oil. 6M HCl (aq) (200ml) was added and reaction stirred at reflux for two hours before concentrating *in vacuo* to give a white solid. This was pre-absorbed onto silica then purified by column chromatography eluting with dichloromethane: methanol: ammonia (90:10:1) to give the title compound as a
5 colourless oil (31.3g, 0.19mol, 94%). ^1H NMR (CDCl_3 , 400MHz) δ : 1.60 (bs, 2H), 2.80 (dd, 1H), 3.02 (dd, 1H), 3.46 (s, 1H), 3.81 (s, 3H), 4.60 (dd, 1H), 6.81 (d, 1H), 6.91 (d, 1H), 6.93 (s, 1H), 7.22 (t, 1H). LRMS: m/z 168 ($\text{M}-\text{H}^+$). Analysis found C, 56.66; H, 8.28; N, 6.91%. $\text{C}_9\text{H}_{13}\text{NO}_2 \cdot 1.33\text{H}_2\text{O}$ requires C, 56.33; H, 8.27; N, 7.30%.


10

EXAMPLE 2N-[2-Hydroxy-2-(3-methoxyphenyl)ethyl]propionamide

Triethylamine (52ml, 0.37mol) was added to the amine from example 1 (31.3g, 0.19mol) in dichloromethane (400ml) and reaction mixture stirred under an
15 atmosphere of nitrogen gas at 0°C for 10 minutes. Propionyl chloride (16.3ml, 0.19mol) was added and after stirring for 30 minutes, the reaction temperature was raised to room temperature for a further 5 hours. The reaction mixture was quenched 1N HCl (aq) (100ml) and then extracted with dichloromethane (2 x
20 50ml). The organic fractions were combined, dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as a colourless oil that crystallised on standing to white crystals (28g, 0.13mol, 67%).
 ^1H NMR (CDCl_3 , 400MHz) δ : 1.18 (t, 3H), 2.22 (q, 2H), 2.51 (bs, 1H), 3.31 (m, 1H), 3.71 (dd, 1H), 3.80 (s, 3H), 4.81 (m, 1H), 5.95 (bs, 1H), 6.80 (d, 1H), 6.90
25 (d, 1H), 6.91 (s, 1H), 7.22 (t, 1H). LRMS: m/z 224. Mpt: 77-78°C. Analysis found C, 63.86; H, 7.82; N, 6.28%. $\text{C}_{12}\text{H}_{17}\text{NO}_3 \cdot 0.1\text{H}_2\text{O}$ requires C, 64.04; H, 7.70; N, 6.22%.

EXAMPLE 3**1-(3-Methoxyphenyl)-2-propylaminoethanol**


Borane-tetrahydrofuran complex (1M in THF) (376ml, 0.4mol) was added to
5 amide from example 2 (28g, 0.13mol) in dry THF (100ml) then the reaction
mixture, stirred under an atmosphere of nitrogen gas, was brought to reflux for
2.5 hours. The reaction mixture was cooled then quenched with methanol
(40ml), before concentrating *in vacuo* to give an opaque white oil. 6N HCl (aq)
(200ml) was added and reaction stirred at reflux for two hours. The reaction
10 mixture was cooled then dichloromethane (200ml) added and the layers
separated. The aqueous layer was rendered basic by addition of potassium
carbonate then re-extracted with dichloromethane (2 x 200ml). Organic extracts
were combined, dried over anhydrous magnesium sulphate, filtered and
concentrated *in vacuo* to give the title compound as a colourless oil that
15 crystallised on standing to give colourless crystals (15.3g, 0.07mol, 59%). ¹H
NMR (CDCl₃, 400MHz) δ: 0.93 (t, 3H), 1.62 (q, 2H), 2.71 (q, 2H), 2.81 (t, 2H),
3.00 (d, 1H), 3.80 (s, 3H), 4.30 (bs, 1H), 4.89 (d, 1H), 6.81 (d, 1H), 6.91 (d, 1H),
6.93 (s, 1H), 7.22 (t, 1H). LRMS: m/z 210. Mpt: 50-51°C. Analysis found C,
67.47; H, 9.02; N, 6.45%. C₁₂H₁₉NO₂·0.2H₂O requires C, 67.70; H, 9.19; N,
20 6.58%.

EXAMPLE 4**2-Chloro-N-[2-hydroxy-2-(3-methoxyphenyl)ethyl]-N-propylacetamide**


Sodium hydroxide (15.1g, 0.38mol) in water (180ml) was added to the amine from example 3 (15.8g, 0.08mol) in dichloromethane (500ml) and the solution vigorously stirred at room temperature. Chloroacetylchloride (7.22ml, 0.09mol) was then added and the reaction mixture stirred for a further 30 minutes. The layers were separated and the aqueous layer re-extracted with dichloromethane (200ml). The organic extracts were combined, dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as a colourless oil (17.8g, 0.06mol, 83%). ¹H NMR (CDCl₃, 400MHz) δ: 0.96 (t, 3H), 1.62 (q, 2H), 3.21 (q, 2H), 3.57-3.71 (m, 2H), 3.82 (s, 3H), 4.01-4.21 (bq, 1H), 4.16 (s, 2H), 5.00 (m, 1H), 6.82 (m, 1H), 6.91-6.99 (m, 2H), 7.22 (m, 1H). LRMS: m/z 286. Analysis found C, 57.38; H, 6.95; N, 4.67%. C₁₄H₂₀NO₃Cl·0.33H₂O requires C, 57.64; H, 7.14; N, 4.80%.

EXAMPLE 5

15 6-(3-Methoxyphenyl)-4-propylmorpholin-3-one




Potassium hydroxide (4.2g, 0.07mol), isopropyl alcohol (500ml) and the amide from example 4 (17.8g, 0.06mol) were stirred together as an opaque solution with water (15ml) for 2 hours. The reaction mixture was concentrated *in vacuo* and the yellow residue dissolved in ethyl acetate (200ml). This was partitioned with water (200ml) then brine (200ml). The organic fraction was dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as a yellow oil (15.8g, 0.06mol, 100%). ¹H NMR (CDCl₃, 400MHz) δ: 0.96 (t, 3H), 1.62 (m, 2H), 3.36 (m, 2H), 3.51 (q, 2H), 3.81 (s, 3H), 4.30-4.62 (bq, 2H), 4.79 (d, 1H), 6.85 (d, 1H), 6.91 (d, 1H), 6.95 (s, 1H), 7.29 (t, 1H). LRMS: m/z 272. Analysis found C, 66.80; H, 7.78; N, 5.52%. C₁₄H₁₉NO₃·0.1H₂O requires C, 66.96; H, 7.71; N, 5.58 %.

EXAMPLE 62-(3-Methoxyphenyl)-4-propylmorpholine

Borane-tetrahydrofuran complex (1M in THF) (200ml, 0.19mol) was added
5 dropwise to the morpholin-3-one from example 5 (15.8g, 0.06mol) in dry THF
(100ml) under an atmosphere of nitrogen, over 30 minutes. The reaction
mixture was brought to reflux for 3 hours then cooled and quenched by addition
of methanol (30ml). The reaction mixture was then concentrated *in vacuo* and
the colourless residue cautiously suspended in 4N HCl (aq) (400ml) before
10 refluxing for 2.5 hours. The reaction mixture was cooled and dichloromethane
(200ml) added. Layers were separated and the aqueous layer rendered basic
by addition of potassium carbonate before re-extracting with dichloromethane
(3 x 100ml). The organic extracts were combined, dried over anhydrous
magnesium sulphate, filtered and concentrated *in vacuo* to give the title
15 compound as a colourless oil (12.51g, 0.05mol, 84%). ¹H NMR (CDCl₃,
400MHz) δ: 0.95 (t, 3H), 1.59 (q, 2H), 2.05 (t, 1H), 2.23 (t, 1H), 2.40 (t, 2H),
2.81 (d, 1H), 2.98 (d, 1H), 3.80 (s, 3H), 3.85 (t, 1H), 4.05 (d, 1H), 4.60 (d, 1H),
6.81 (d, 1H), 6.91 (d, 1H), 7.21 (t, 1H), 7.23 (s, 1H). LRMS: m/z 236. Analysis
found C, 68.94; H, 8.80; N, 5.79%. C₁₄H₂₁NO₂·0.5H₂O requires C, 68.82; H,
20 9.08; N, 5.73%.

EXAMPLE 7AR-(-)-3-(4-Propylmorpholin-2-yl)phenolExample 7b


25 S-(+)-3-(4-Propylmorpholin-2-yl)phenol



Hydrobromic acid (250ml) and the anisole from example 6 (8.62g, 0.03mol) were heated to reflux together for 1 hour. After cooling the reaction mixture was diluted with water (100ml) then neutralised by addition of NH_4OH (20ml). The yellow opaque solution was then extracted with dichloromethane (2 x 100ml). The organic extracts were combined then dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the racemic mixture of the title compound as a yellow oil (7.78g, 0.03mol, 96%). The enantiomers were separated by chiral chromatography (Chiralpak AD 250 * 20mm column) eluting with hexane: isopropyl alcohol: diethylamine (70: 30: 0.05) to give enantiomer 1 (ee > 99.5%) and enantiomer 2 (ee > 99%). Each enantiomer was purified by column chromatography on silica eluting with dichloromethane: methanol (95:5) to give enantiomer 1(7a) (3.02g, 0.014mol, 39%) and enantiomer 2 (7b) (3.15g, 0.014mol, 40%) as colourless oils. Enantiomer 1 (7a): ^1H NMR (CDCl_3 , 400MHz) δ : 0.96 (t, 3H), 1.60 (q, 2H), 2.13 (t, 1H), 2.31 (t, 1H), 2.41 (t, 2H), 2.85 (d, 1H), 3.02 (d, 1H), 3.90 (t, 1H), 4.02 (dd, 1H), 4.60 (d, 1H), 6.78 (d, 1H), 6.80 (s, 1H), 6.91 (d, 1H), 7.20 (t, 1H). LRMS: m/z 222 ($\text{M}-\text{H}^+$). Enantiomer 2 (7b): ^1H NMR (CDCl_3 , 400MHz) δ : 0.96 (t, 3H), 1.60 (q, 2H), 2.13 (t, 1H), 2.31 (t, 1H), 2.41 (t, 2H), 2.85 (d, 1H), 3.02 (d, 1H), 3.90 (t, 1H), 4.02 (dd, 1H), 4.60 (d, 1H), 6.78 (d, 1H), 6.80 (s, 1H), 6.91 (d, 1H), 7.20 (t, 1H). LRMS: m/z 222 ($\text{M}-\text{H}^+$).

EXAMPLE 8

R-(-)-3-(4-Propylmorpholin-2-yl)phenol hydrochloride




Enantiomer 1 (7a) of example 7 (3.00g, 0.014mol) was dissolved in diethyl ether (180ml) and hydrogen chloride (2.0M solution in diethyl ether) (10ml) was added. The reaction mixture was stirred at room temperature for 30 minutes, then the solvent was decanted and dried *in vacuo*, giving title compound as a white solid (3.115g, 0.012mol, 90%). ¹H NMR (CD₃OD, 400MHz) δ : 1.06 (t, 3H), 1.81 (m, 2H), 3.02 (t, 1H), 3.16 (t, 2H), 3.20 (t, 1H), 3.60 (t, 2H), 4.01 (t, 1H), 4.26 (d, 1H), 4.71 (d, 1H), 6.78 (d, 1H), 6.82 (s, 1H), 6.83 (d, 1H), 7.21 (t, 1H). LRMS: m/z 222 (M-H⁺). Analysis found C, 59.74; H, 7.98; N, 5.25%. C₁₃H₁₉NO₂·0.18H₂O requires C, 59.82; H, 7.86; N, 5.37%. $\alpha_D = -5.66^\circ$ (Methanol 10.6mg/ 10ml).

A SAMPLE OF THE TITLE COMPOUND WAS RE CRYSTALLISED BY VAPOUR DIFFUSION USING A METHANOL: DIETHYL ETHER MIX AND AN X-RAY CRYSTAL STRUCTURE OBTAINED. THE ABSOLUTE STEREOCHEMISTRY OF THE TITLE COMPOUND WAS DETERMINED FROM THE DIFFRACTION DATA BY THE METHOD OF FLACK¹ AND WAS SHOWN TO HAVE AN 'R' CONFIGURATION.

REF 1: H.D.FLACK, *ACTA CRYST.* 1983, 439, 876-881

20 EXAMPLE 9

2-Amino-1-(3,5-dimethoxyphenyl)ethanol




Prepared following the same method as for example 1 starting from 3,5-dimethoxybenzaldehyde (5.00g, 0.03mol). After refluxing in 6M HCl (aq) the reaction mixture was cooled and extracted with diethyl ether (2 x 80ml). The

organic layers were discarded and the aqueous layer basified by the addition of potassium carbonate. The aqueous residue was then extracted with ethyl acetate (3 x 70ml). The organic extracts were combined and dried over anhydrous magnesium sulphate, filtered and concentrated in vacuo to give the
5 title compound as a pale yellow oil (3.47g, 0.018mol, 59%). ^1H NMR (CD_3OD , 400MHz) δ : 2.77 – 2.86 (m, 2H), 3.78 (s, 6H), 4.60 (m, 1H), 6.38 (s, 1H), 6.52 (s, 2H). LRMS: m/z 198 ($\text{M}-\text{H}^+$).

EXAMPLE 10


10 N-[2-(3,5-dimethoxyphenyl)-2-hydroxyethyl]propionamide



Prepared following the same method as for example 2 starting from the amine in example 9 (3.41g, 0.017mol). The crude reaction mixture was purified by column chromatography on silica eluting with dichloromethane: methanol (95:5)
15 to give the title compound as a bright yellow oil (3.08g, 0.012mol, 70%). ^1H NMR (CDCl_3 , 400MHz) δ : 1.18 (m, 3H), 2.24 (m, 2H), 3.34 (m, 1H), 3.68 (m, 1H), 3.81 (s, 6H), 4.80 (dd, 1H), 5.95 (bs, 1H), 6.39 (s, 1H), 6.51 (s, 2H). LRMS: m/z 252 ($\text{M}-\text{H}^+$).

20 EXAMPLE 11


1-(3,5-dimethoxyphenyl)-2-propylaminoethanol



Prepared following the method as for example 3 starting from the amide in example 10 (3.06g, 0.012mol) to give the title compound as an orange oil (2.72g, 0.011mol, 94%). ^1H NMR (CD_3OD , 400MHz) δ : 0.95 (t, 3H), 1.56 (m, 2H), 2.61 (m, 2H), 2.77 (d, 2H), 3.78 (s, 6H), 4.70 (t, 1H), 6.38 (s, 1H), 6.51 (s, 2H). LRMS: m/z 240 ($\text{M}-\text{H}^+$).

EXAMPLE 12

2-Chloro-N-[2--(3,5-dimethoxyphenyl)-2-hydroxyethyl]-N-propylacetamide




10 Prepared following the same method as for example 4 starting from the amine in example 11 (2.70g, 0.011mol) to give the title compound as a yellow oil (3.56g, 0.011mol, 100%). ^1H NMR (CDCl_3 , 400MHz) δ : 0.92 (t, 3H), 1.61 (m, 2H), 3.20 (m, 2H), 3.51–3.64 (m, 2H), 3.80 (d, 6H), 4.13 (s, 2H), 4.95 (m, 1H), 6.40 (m, 1H), 6.55 (s, 2H). LRMS: m/z 316 ($\text{M}-\text{H}^+$).

15

EXAMPLE 13

6-(3,5-Dimethoxyphenyl)-4-propylmorpholin-3-one




Prepared following the same method as for example 5 starting from the amide in example 12 (3.54g, 0.011mol) to give the title compound as a yellow oil

20

(2.44g, 0.009mol, 78%). ^1H NMR (CDCl_3 , 400MHz) δ : 0.94 (t, 3H), 1.61 (m, 2H), 3.30 (m, 2H), 3.49 (m, 2H), 3.80 (s, 6H), 4.30 (d, 1H), 4.42 (d, 1H), 4.73 (dd, 1H), 6.42 (s, 1H), 6.53 (s, 2H). LRMS: m/z 280 (M-H^+).

5 EXAMPLE 14

2-(3,5-Dimethoxyphenyl)-4-propylmorpholine




Prepared following the method as for example 6 starting from the amide in example 13 (2.42g, 0.009mol). After refluxing in 6M HCl (aq) the cooled
10 reaction mixture was extracted with diethyl ether (2 x 80ml). The organic layers were discarded and the aqueous basified by addition of potassium carbonate. The aqueous residue was then extracted with ethyl acetate (3 x 80ml) and the organic extracts combined, dried over anhydrous magnesium sulphate, filtered then concentrated *in vacuo* to give the title compound as a pale orange oil
15 (2.14g, 0.008mol, 93%). ^1H NMR (CD_3OD , 400MHz) δ : 0.95 (t, 3H), 1.58 (m, 2H), 2.01 (m, 1H), 2.22 (dt, 1H), 2.38 (t, 2H), 2.83 (d, 1H), 2.93 (d, 1H), 3.78 (m, 7H), 4.01 (dd, 1H), 4.45 (dd, 1H), 6.39 (s, 1H), 6.49 (s, 2H). LRMS: m/z 266 (M-H^+).

20 EXAMPLE 15A

R-5-(4-Propylmorpholin-2-yl)benzene-1, 3-diol

Example 15b


S-5-(4-Propylmorpholin-2-yl)benzene-1, 3-diol




Prepared following the same route as for example 7 starting from the 3,5-dimethoxyphenyl compound in example 14 (1.00g, 0.004mol) giving the title racemic compound as a brown oil (145mg, 0.61mmol, 16%). The enantiomers were separated by chiral chromatography (Chiralpak AD 250 * 20mm column) eluting with hexane: isopropyl alcohol: (80: 20) to give enantiomer 1 (15a) (5.2mg) (ee > 98.94%) and enantiomer 2 (15b) (5.1mg) (ee > 96.46%) as brown oils. Enantiomer 1 (15a): ^1H NMR (CD_3OD , 400MHz) δ : 0.96 (t, 3H), 1.58 (m, 2H), 2.01 (t, 1H), 2.20 (dt, 1H), 2.37 (t, 2H), 2.81 - 2.92 (m, 2H), 3.89 (dt, 1H), 3.99 (dd, 1H), 4.38 (dd, 1H), 6.18 (t, 1H), 6.26 (s, 2H). LRMS: m/z 238 ($\text{M}-\text{H}^+$). Enantiomer 2 (15b): ^1H NMR (CD_3OD , 400MHz) δ : 0.95 (t, 3H), 1.58 (m, 2H), 2.01 (t, 1H), 2.20 (dt, 1H), 2.38 (t, 2H), 2.80 - 2.92 (q, 2H), 3.78 (dt, 1H), 3.98 (dd, 1H), 4.38 (dd, 1H), 6.18 (s, 1H), 6.25 (s, 2H). LRMS: m/z 238 ($\text{M}-\text{H}^+$).

15 EXAMPLE 16

4-Fluoro-3-methoxybenzaldehyde




(4-Fluoro-3-methoxyphenyl) methanol (5.00g, 0.03mol) and manganese dioxide (33.4g, 0.38mol) were stirred in dichloromethane (100ml) under an atmosphere of nitrogen, at gentle reflux for 16 hours. The cooled reaction mixture was then filtered through arbacel and concentrated *in vacuo* to give the title compound as a white solid (4.18g, 0.027mol, 85%). ^1H NMR (CDCl_3 , 400MHz) δ : 3.96 (s, 3H), 7.23 (d, 1H), 7.43 (m, 1H), 7.50 (d, 1H) 9.91 (s, 1H). Mpt: 61-63°C. Analysis found C, 62.18; H, 4.54%. $\text{C}_8\text{H}_7\text{FO}_2$ requires C, 62.34; H, 4.58%.


EXAMPLE 172-Amino-1-(4-fluoro-3-methoxyphenyl)ethanol

- 5 Prepared following the same method as for example 1 starting from 4-fluoro-3-methoxybenzaldehyde (4.17g, 0.03mol). After refluxing in 6M HCl (aq) the reaction mixture was cooled and extracted with diethyl ether (2 x 60ml). The organic layers were discarded and the aqueous layer basified by the addition of potassium carbonate. The aqueous residue was then extracted with ethyl
- 10 acetate (3 x 80ml). The organic extracts were combined and dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as an orange oil (2.36g, 0.013mol, 47%). ¹H NMR (CD₃OD, 400MHz) δ: 2.80 –2.91 (m, 2H), 3.86 (s, 3H), 4.64 (m, 1H), 6.89 (m, 1H), 7.03 (t, 1H), 7.11 (dd, 1H). LRMS: m/z 186 (M-H⁺).

15


EXAMPLE 18N-[2-(4-Fluoro-3-methoxyphenyl)-2-hydroxyethyl]propionamide

- Prepared following the same method as for example 2 starting with the amine
- 20 from example 17 (1.32g, 0.007mol). The crude reaction mixture was purified by column chromatography on silica eluting with ethyl acetate: pentane (2:1) to give the title compound as a yellow oil that crystallised on standing (0.59g, 0.002mol, 35%). ¹H NMR (CDCl₃, 400MHz) δ: 1.18 (t, 3H), 2.24 (q, 2H), 2.58 (bs, 1H), 3.34 (m, 1H), 3.63 (m, 1H), 3.88 (s, 3H), 4.82 (dd, 1H), 5.98 (bs, 1H),
- 25 6.82 (m, 1H), 7.01 (m, 2H). LRMS: m/z 242 (M-H⁺).


EXAMPLE 19**1-(4-Fluoro-3-methoxyphenyl)-2-propylaminoethanol**

- 5 Prepared following the same method as for example 3 starting with the amide from example 18 (585mg, 2.42mmol). After refluxing in 6M HCl (aq) the reaction mixture was cooled and extracted with diethyl ether (2 x 50ml). The organic layers were discarded and the aqueous layer basified by the addition of potassium carbonate. The aqueous residue was then extracted with ethyl
- 10 acetate (3 x 50ml). The organic extracts were combined and dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as a pale yellow oil (448mg, 1.97mmol, 81%). ¹H NMR (CD₃OD, 400MHz) δ : 0.96 (t, 3H), 1.58 (m, 2H), 2.63 (m, 2H), 2.79 (d, 2H), 3.96 (s, 3H), 4.77 (t, 1H), 6.90 (m, 1H), 7.03 (t, 1H), 7.11 (d, 1H). LRMS: m/z 228 (M-H⁺).


15

EXAMPLE 20**2-Chloro-N-[2-(4-fluoro-3-methoxyphenyl)-2-hydroxyethyl]-N-propylacetamide**


- 20 Prepared following the same method as for example 4 starting with the amine from example 19 (0.84g, 4.00mmol) to give the title compound as a yellow oil (0.97g, 3.00mmol, 87%). LRMS: m/z 304 (M-H⁺). This was taken on crude.

EXAMPLE 216-(4-Fluoro-3-methoxyphenyl)-4-propylmorpholin-3-one

Prepared following the same method as for example 5 starting with the amide
5 from example 20 (0.96g, 3.00mmol) to give the title compound as a yellow oil (0.64g, 2.40mmol, 75%). ¹H NMR (CDCl₃, 400MHz) δ: 0.94 (t, 3H), 1.62 (m, 2H), 3.33 (m, 2H), 3.48 (m, 2H), 3.91 (s, 3H), 4.34 (d, 1H), 4.43 (d, 1H), 4.76 (dd, 1H), 6.85 (m, 1H), 7.01 - 7.08 (m, 2H). LRMS: m/z 268 (M-H⁺).

10 EXAMPLE 222-(4-Fluoro-3-methoxyphenyl)-4-propylmorpholine

Prepared following the same method as for example 6 starting with the
morpholin-3-one from example 21 (633mg, 2.37mmol). After refluxing in 6M
15 HCl (aq) the reaction mixture was cooled and extracted with diethyl ether (2 x 20ml). The organic layers were discarded and the aqueous layer basified by the addition of potassium carbonate. The aqueous residue was then extracted with ethyl acetate (3 x 20ml). The organic extracts were combined and dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the
20 title compound as a yellow oil (552mg, 2.18mmol, 92%). ¹H NMR (CD₃OD, 400MHz) δ: 0.95 (t, 3H), 1.58 (m, 2H), 2.02 (t, 1H), 2.22 (dt, 1H), 2.38 (t, 2H), 2.85 (d, 1H), 2.93 (d, 1H), 3.80 (m, 1H), 3.84 (s, 3H), 4.01 (dd, 1H), 4.50 (dd, 1H), 6.88 (m, 1H), 7.02 (t, 1H), 7.09 (d, 1H). LRMS: m/z 254 (M-H⁺).


EXAMPLE 23AR-(+)-2-Fluoro-5-(4-propylmorpholin-2-yl)phenolExample 23bS-(-)-2-Fluoro-5-(4-propylmorpholin-2-yl)phenol

5


Prepared following the same method as for example 7 starting with the anisole from example 22 (200mg, 0.789mmol). The crude reaction mixture was purified by column chromatography on silica eluting with dichloromethane: methanol (90:10) to give the title racemic compound as a dark yellow viscous oil (149mg, 0.62mmol, 79%). The enantiomers were separated by chiral chromatography (Chiralpak AD 250 * 20mm column) eluting with hexane: isopropyl alcohol: (90:10) to give enantiomer 1 (23a) as an opaque oil (15mg) (ee > 99.5%) and enantiomer 2 (23b) as a crystalline solid (16mg) (ee > 99%). Enantiomer 1 (23a): ^1H NMR (CD_3OD , 400MHz) δ : 0.95 (t, 3H), 1.58 (m, 2H), 2.01 (t, 1H), 2.21 (dt, 1H), 2.37 (t, 2H), 2.82 - 2.97 (bq, 2H), 3.78 (dt, 1H), 3.99 (dd, 1H), 4.43 (d, 1H), 6.78 (m, 1H), 6.89 - 7.01 (m, 2H). LRMS: m/z 240 ($\text{M}-\text{H}^+$). $\alpha_D = +0.91$ (Ethanol 1.10mg/ ml). Enantiomer 2 (23b): ^1H NMR (CD_3OD , 400MHz) δ : 0.96 (t, 3H), 1.58 (m, 2H), 2.01 (t, 1H), 2.22 (dt, 1H), 2.38 (t, 2H), 2.78 (dd, 2H), 3.78 (dt, 1H), 4.00 (dd, 1H), 4.43 (dd, 1H), 6.78 (m, 1H), 6.91 (d, 1H), 6.98 (t, 1H). LRMS: m/z 240 ($\text{M}-\text{H}^+$). $\alpha_D = -0.40$ (Ethanol 1.00mg/ ml).

20

EXAMPLE 242-Amino-1-(4-benzyloxyphenyl)ethanol




Potassium cyanide (20.15g, 0.31mol) and ammonium chloride (16.4g, 0.31mol) were dissolved in water (60ml) to which was added 4-benzyloxybenzaldehyde (32.9g, 0.155mol) followed by diethyl ether (100ml). The reaction mixture was stirred vigorously for 48 hours at room temperature before extracting with ethyl acetate (2 x 200ml). The combined organic layers were dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the cyanohydrin intermediate as a yellow solid (34.2g, 0.14mol, 90%). The cyanohydrin was then dissolved in dry THF (300ml) and borane-methyl sulphide complex (26.6ml, 0.28mol) was added. The reaction mixture was refluxed for 2 hours before being quenched with methanol (50ml). Water (50ml) was added followed by c.HCl (40ml) and the reaction mixture was stirred for 2 hours until the exotherm subsided. The reaction mixture was then concentrated *in vacuo* and the residue diluted with water (100ml). The aqueous solution was then basified by addition of NH₄OH (30ml), and extracted with ethyl acetate (3 x 150ml). The organic extracts were dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as a white solid (24.8g, 0.10mol, 73%). ¹H NMR (CDCl₃, 400MHz) δ: 1.62 (bs, 3H), 2.81 (dd, 1H), 2.99 (d, 1H), 4.61 (q, 1H), 5.07 (s, 2H), 6.95 (d, 2H), 7.22-7.45 (m, 7H). LRMS: m/z 244 (M-H⁺).

EXAMPLE 25**N-[2-(4-BENZYLOXYLPHENYL)-2-HYDROXYETHYL]PROPIONAMIDE**

The amine from example 24 (24.8g, 0.10mol) was dissolved in dichloromethane
5 (700ml) and to this was added triethylamine (20.86ml, 0.15mol). The reaction
mixture was stirred and cooled to 0°C, before propionyl chloride (7.12ml,
0.082mol) was added dropwise. The reaction mixture was then allowed to warm
to room temperature over 16 hours before quenching with 3M HCl (aq) (20ml)
and water (100ml). The reaction mixture was then extracted with
10 dichloromethane (3 x 200ml) and the combined organic layers dried over
anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the
title compound as a clear viscous gum (27.5g, 0.092mol, 90%). ¹H NMR
(CDCl₃, 400MHz) δ: 1.10 (t, 3H), 2.19 (q, 2H), 3.32-3.43 (m, 4H), 4.81 (s, 2H),
5.11 (m, 1H), 6.99 (d, 2H), 7.25- 7.42 (m, 7H). LRMS: m/z 298 (M-H⁺).


15

EXAMPLE 261-(4-benzyloxyphenyl)-2-propylaminoethanol

To the amide from example 25 (27.5g, 0.092mol) in dry THF (100ml) was
20 added borane-methyl sulphide complex (17.5ml, 0.18mol) and the reaction
mixture was stirred at reflux for 2 hours. The reaction mixture was cooled then

quenched with methanol (30ml). Water (50ml) and c.HCl (35ml) were added and the reaction mixture stirred until all bubbling ceased before concentrating *in vacuo*. To the residue water (250ml) was added, before basifying by addition of NH₄OH (30ml). The aqueous layer was extracted with ethyl acetate (3 x 200ml) and the combined organic extracts dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as a white solid (26.1g, 0.09mol, 99%). ¹H NMR (CD₃OD, 400MHz) δ : 0.95 (t, 3H), 1.58 (q, 2H), 2.62 (m, 2H), 2.81 (m, 2H), 4.72 (dd, 1H), 5.05 (s, 2H), 6.95 (d, 2H), 7.24 (m, 3H), 7.35 (t, 2H), 7.41 (d, 2H). LRMS: m/z 286 (M-H⁺).


10

EXAMPLE 276-(4-benzyloxyphenyl)-4-propylmorpholin-3-one

Sodium hydroxide (22.5g, 0.56mol) in water (100ml) was added to the amine from example 26 (26.0g, 0.09mol) in dichloromethane (400ml) and the solution vigorously stirred at room temperature. Chloroacetylchloride (8.6ml, 0.11mol) was then added and the reaction mixture stirred for a further 60 minutes. The layers were separated and the aqueous layer re-extracted with dichloromethane (200ml). The organic extracts were combined, dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give a colourless oil. Potassium hydroxide (15.0g, 0.27mol), isopropyl alcohol (400ml) and the colourless oil residue were stirred together as an opaque solution with water (30ml) for 2 hours. The reaction mixture was concentrated *in vacuo* and the yellow residue dissolved in ethyl acetate (200ml). This was partitioned with water (200ml) then brine (200ml). The organic fraction was dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the


title compound as a white solid (19.9g, 0.06mol, 67%). ^1H NMR (CDCl_3 , 400MHz) δ : 0.95 (t, 3H), 1.62 (m, 2H), 3.34 (m, 2H), 3.51 (m, 2H), 4.32 (d, 1H), 4.41 (d, 1H), 4.72 (dd, 1H), 5.04 (s, 2H), 6.98 (d, 2H), 7.31-7.43 (m, 7H). LRMS: m/z 326 ($\text{M}-\text{H}^+$).

5

EXAMPLE 282-(4-benzyloxyphenyl)-4-propylmorpholine

Prepared following the same method as for example 26 with the morpholin-3-one from example 27 (19.9g, 0.061mol) to give the title compound as a colourless oil (17g, 0.055mol, 90%). ^1H NMR (CDCl_3 , 400MHz) δ : 0.95 (t, 3H), 1.55 (q, 2H), 2.06 (t, 1H), 2.21 (dt, 1H), 2.35 (dd, 2H), 2.80 (d, 1H), 2.91 (d, 1H), 3.82 (dt, 1H), 4.02 (dd, 1H), 4.52 (dd, 1H), 5.05 (s, 2H), 6.98 (t, 2H), 7.24-7.42 (m, 7H). LRMS: m/z 312 ($\text{M}-\text{H}^+$).

15


EXAMPLE 294-(4-Propylmorpholin-2-yl)phenol

Benzyl ether from example 28 (3.0g, 9.64mmol) was dissolved in methanol (150ml) and 10% palladium on charcoal (800mg) was added. The reaction mixture was stirred for a few minutes before ammonium formate (6.17g, 96.4mmol) was added portionwise. The reaction mixture was carefully heated

to 80°C until gas evolution had ceased. After cooling, the reaction mixture was filtered through arbacel, washed with methanol (50ml) and concentrated *in vacuo* to give the title compound as a white crystalline solid (1.51g, 6.83mmol, 71%). ¹H NMR (CDCl₃, 400MHz) δ: 0.91 (t, 3H), 1.58 (q, 2H), 2.10 (t, 1H), 2.22 (t, 1H), 2.40 (dd, 2H), 2.81 (d, 1H), 2.93 (d, 1H), 3.85 (t, 1H), 4.02 (dd, 1H), 4.57 (d, 1H), 6.79 (d, 2H), 7.21 (d, 2H). LRMS: m/z 222 (M-H⁺).

EXAMPLE 30

2-Bromo-4-(4-propylmorpholin-2-yl)phenol




10

To the phenol from example 29 (200mg, 0.9mmol) in dichloromethane (5ml) was added N-bromosuccinimide (161mg, 0.9mmol). The reaction mixture was stirred at room temperature for 55 hours, before concentrating *in vacuo*. The crude product was purified by column chromatography on silica eluting with dichloromethane: methanol (95:5) to give the title compound as a white foam (117.5mg, 0.39mmol, 44%). ¹H NMR (CDCl₃, 400MHz) δ: 0.96 (t, 3H), 1.59 (q, 2H), 2.03 (t, 1H), 2.23 (t, 1H), 2.40 (t, 2H), 2.81 (d, 1H), 2.98 (d, 1H), 3.82 (t, 1H), 4.01 (d, 1H), 4.56 (d, 1H), 6.96 (d, 1H), 7.20 (d, 1H), 7.49 (s, 1H). LRMS: m/z 302 (M-H⁺, Br isotope).

20

EXAMPLE 31


2-(4-benzyloxy-3-bromophenyl)-4-propylmorpholine



To the phenol from example 30 (117.5mg, 0.39mmol) in dry DMF (10ml), under an atmosphere of nitrogen, was added potassium carbonate (75mg, 0.54mmol) and benzyl bromide (0.07ml, 0.54mmol). The reaction mixture was heated to
5 150°C for 48 hours. After cooling, the reaction mixture was concentrated *in vacuo* and the residue partitioned between ethyl acetate (50ml) and water (50ml). The aqueous layer was then re-extracted with ethyl acetate (2 x 20ml). The combined organic extracts were then dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the crude product as a
10 brown oil. This was purified by column chromatography on silica eluting with dichloromethane: methanol (98:2) to give the title compound as a colourless oil (153mg, 0.39mmol, 100%). ¹H NMR (CDCl₃, 400MHz) δ : 0.93 (t, 3H), 1.56 (q, 2H), 2.05 (t, 1H), 2.25 (t, 1H), 2.37 (t, 2H), 2.82 (d, 1H), 2.92 (d, 1H), 3.85 (t, 1H), 4.02 (d, 1H), 4.52 (d, 1H), 5.15 (s, 2H), 6.87 (d, 1H), 7.20 (d, 1H), 7.30 (d,
15 1H), 7.37 (t, 2H), 7.45 (d, 2H), 7.58 (s, 1H). LRMS: m/z 392 (M-H⁺).

EXAMPLE 32


2-Benzyloxy-5-(4-propylmorpholin-2-yl)benzoic acid methyl ester



20 To the bromide from example 31 (153mg, 0.39mmol) in dry DMF (4ml) was added triethylamine (2.1ml, 0.78mmol) and methanol (2ml) and the reaction mixture stirred for 5 minutes. [1,1'-


Bis(diphenylphosphino)ferrocene]dichloropalladium (II), complex with dichloromethane (1:1) (16mg, 0.02mmol) was added before carbon monoxide (g) (3 inflated balloons) was bubbled through the reaction mixture. The reaction mixture was then heated to 100°C for 16 hours under an atmosphere of carbon monoxide. After cooling, the reaction mixture was concentrated *in vacuo* and the residue partitioned between ethyl acetate (25ml) and water (20ml). The organic layer was separated, washed with brine (20ml) and dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give a black solid. Purification by column chromatography on silica eluting with dichloromethane: methanol: ammonia (90:10:1) gave the title compound as a colourless oil (105mg, 0.28mmol, 73%). ¹H NMR (CDCl₃, 400MHz) δ: 0.94 (t, 3H), 1.60 (m, 2H), 2.18 (s, 4H), 2.43 (m, 2H), 3.00 (m, 2H), 3.90 (s, 3H), 4.04 d, 1H), 5.18 (s, 2H), 5.97 (d, 1H), 7.26-7.47 (m, 6H), 7.82 (s, 1H). LRMS: m/z 370 (M-H⁺).

15


EXAMPLE 332-Benzyloxy-5-(4-propylmorpholin-2-yl)benzoic acid

To the methyl ester from example 32 (105mg, 0.28mmol) in methanol (5ml) was added 10% sodium hydroxide (aq) (15ml) and the milky white suspension was refluxed for 2 hours. The now colourless reaction mixture was cooled then neutralised by addition of 2M HCl (aq) (few drops). The reaction mixture was then concentrated *in vacuo* to give the title compound as an off-white solid (99mg, 0.28mmol, 100%). LRMS: m/z 355 (M-H⁺). This material was taken on crude to example 34.

25

EXAMPLE 342-Benzyloxy-5-(4-propylmorpholin-2-yl)benzamide

To the crude benzoic acid from example 33 (99mg, 0.28mmol) was added
5 thionyl chloride (5ml) and the reaction mixture heated to 50°C for 2 hours. The
reaction mixture was cooled and the excess thionyl chloride was removed *in*
vacuo. The residue was then dissolved in dichloromethane (10ml) and
ammonia (g) was bubbled through the reaction mixture for 10 minutes. The
resulting suspension was stirred at room temperature for 1 hour before
10 concentrating *in vacuo*. The crude material was purified by column
chromatography on silica eluting with dichloromethane: methanol: ammonia
(95:5:0.5) to give the title compound as an off-white solid (88mg, 0.25mmol,
90%). ¹H NMR (CDCl₃, 400MHz) δ : 0.94 (t, 3H), 1.59 (m, 2H), 2.15-2.42 (m,
4H), 2.87 (m, 1H), 3.03 (m, 1H), 3.96 (m, 1H), 4.02 (d, 1H), 4.67 (m, 1H), 5.19
15 (s, 2H), 5.72 (m, 1H), 7.04 (d, 1H), 7.41 (m, 5H), 7.50 (d, 1H), 7.70 (m, 1H),
8.21 (s, 1H). LRMS: m/z 355 (M-H⁺).


EXAMPLE 352-Hydroxy-5-(4-propylmorpholin-2-yl)benzamide

20


Prepared using the same method as for example 29 with the benzyl ester from
example 34 (80mg, 0.22mmol) to give the title compound as an off-white solid

(56mg, 0.21mmol, 96%). ^1H NMR (CD_3OD , 400MHz) δ : 0.95 (t, 3H), 1.55 (m, 2H), 2.13 (t, 1H), 2.29 (t, 1H), 2.42 (m, 2H), 2.88 (d, 1H), 2.97 (d, 1H), 3.81 (t, 1H), 4.00 (d, 1H), 4.49 (d, 1H), 6.87 (d, 1H), 7.42 (d, 1H), 7.78 (s, 1H). LRMS: m/z 265 ($\text{M}-\text{H}^+$).

5

EXAMPLE 362-Nitro-4-(4-propylmorpholin-2-yl)phenol

The phenol from example 29 (100mg, 0.45mmol) was dissolved in nitric acid:
10 water (1:3) (2ml) and stirred at room temperature for 10 minutes. The reaction mixture was then diluted with water (5ml) and basified with NH_4OH (1ml), before extracting into ethyl acetate (3 x 10ml). The organic extracts were combined and dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as a yellow solid (95mg,
15 0.35mmol, 79%). ^1H NMR (CDCl_3 , 400MHz) δ : 0.97 (t, 3H), 1.33 (t, 2H), 1.43-1.79 (bm, 4H), 2.02 (d, 3H), 4.06 (m, 2H), 7.17 (d, 1H), 7.60 (d, 1H), 8.16 (s, 1H), 10.55 (bs, 1H). LRMS: m/z 267 ($\text{M}-\text{H}^+$).

EXAMPLE 3720 2-Amino-4-(4-propylmorpholin-2-yl)phenol


To the nitro from example 36 (95mg, 0.35mmol) in ethanol (10ml) was added 10% palladium on charcoal (50mg) and ammonium formate (100mg, XS). The reaction mixture was gently heated to 70°C and held at this temperature for 1

hour before it was allowed to cool to room temperature. The reaction mixture was then filtered through arbacel and washed with ethanol (20ml) then dichloromethane (20ml). The organic washes were combined and concentrated *in vacuo* to give the title compound as a yellow solid (65mg, 0.28mmol, 78%).

- 5 ^1H NMR (CDCl_3 , 400MHz) δ : 0.91 (t, 3H), 1.55 (m, 2H), 2.12 (t, 1H), 2.25 (dt, 1H), 2.40 (t, 2H), 2.81-2.92 (dd, 2H), 3.82 (t, 1H), 4.00 (d, 1H), 4.42 (d, 1H), 6.60 (m, 2H), 6.71 (s, 1H). LRMS: m/z 237 (M-H^+).

EXAMPLE 38


- 10 5-Bromo-2-(2,5-dimethylpyrrol-1-yl)pyridine



- 5-Bromopyridin-2-yl-amine (13.8g, 0.08mol), acetonylacetone (14.1ml, 0.12mol) and *p*-toluenesulphonic acid (100mg) were dissolved in toluene (180ml) and refluxed under Dean Stark conditions for 14 hours. After cooling, the brown solution was poured into water (200ml) and extracted with toluene (2 x 200ml). The organic extracts were combined and washed with brine (50ml) then dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give crude product. This was purified by column chromatography on silica eluting with ethyl acetate: pentane (1:3) to give the title compound as a brown oil
- 15
20 (18.4g, 0.073mol, 92%). ^1H NMR (CDCl_3 , 400MHz) δ : 2.18 (s, 6H), 5.90 (s, 2H), 7.11 (d, 1H), 7.92 (d, 1H), 8.62 (s, 1H). LRMS: m/z 253 (M-H^+ , Br isotope).


EXAMPLE 39

2-Chloro-1-[6-(2,5-dimethylpyrrol-1-yl)pyridin-3-yl]ethanone



To a solution of bromo pyridine from example 38 (2g, 8.0mmol) at -78°C , in dry THF (30ml), was added butyllithium (2.5M in hexanes) (3.5ml 8.8mmol), dropwise over 20 minutes. The reaction mixture was stirred for 30 minutes then
5 2-chloro-N-methoxy-N-methylacetamide (1.2g, 8.8mmol) in dry THF (20ml) was added dropwise keeping the temperature at -78°C . Stirring was continued for 30 minutes at this temperature before 1M HCl (aq) (50ml) was added and the reaction mixture warmed to room temperature. The organic layer was separated and the aqueous layer washed with ethyl acetate (50ml). The organic
10 layers were combined then washed with 3M NaOH (aq) (10ml) and brine (10ml) before being dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give crude title compound as a brown oil (1.34g, 5.4mmol, 67%). ^1H NMR (CDCl_3 , 400MHz) δ : 2.20 (s, 6H), 4.68 (s, 2H), 5.92 (s, 2H), 7.32 (d, 1H), 8.38 (d, 1H), 9.16 (s, 1H). LRMS: m/z 249 ($\text{M}-\text{H}^+$).

15


EXAMPLE 402-(2,5-dimethylpyrrol-1-yl)-5-oxiranylpuridine

To the ketone from example 39 (1.34g, 5.4mmol) dissolved in dry THF (20ml),
20 cooled to 0°C , was added sodium borohydride (308mg, 8.1mmol) portionwise. The reaction mixture was stirred for 2 hours then 3M NaOH (aq) (10ml) was added and stirring continued for a further 16 hours. The reaction mixture was extracted with ethyl acetate (2 x 20ml) and the combined organic extracts

washed with brine (5ml), dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo*. The residue was purified by column chromatography on silica eluting with ethyl acetate: pentane (1:5) to give the title compound as a colourless oil (900mg, 4.2mmol, 78%). ¹H NMR (CDCl₃, 400MHz) δ: 2.13 (s, 6H), 2.91 (dd, 1H), 3.25 (t, 1H), 3.98 (t, 1H), 5.90 (s, 2H), 7.20 (d, 1H), 7.62 (dd, 1H), 8.58 (s, 1H). LRMS: m/z 215 (M-H⁺).

EXAMPLE 41

1-[6-(2,5-dimethylpyrrol-1-yl)pyridin-3-yl]-2-propylaminoethanol




10

To the epoxide from example 40 (900mg, 4.2mmol) in DMSO (5ml) was added propylamine (4ml, 4.8mmol) and the reaction mixture was heated to 40°C for 4 days. The reaction mixture was then cooled and 3M HCl (aq) (10ml) and water (10ml) were added before washing with diethyl ether (2 x 10ml). This organic layer was discarded. The aqueous layer was basified with NH₄OH (5ml) and extracted with ethyl acetate (3 x 10ml). The organic extracts were combined and dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as an oil (1.15g, 4.2mmol, 100%). ¹H NMR (CDCl₃, 400MHz) δ: 0.93 (t, 3H), 1.62 (m, 2H), 2.11 (s, 6H), 2.69-2.82 (m, 3H), 3.06 (dd, 1H), 3.60 (bs, 2H), 4.92 (dd, 1H), 5.84 (s, 2H), 7.20 (d, 1H), 7.88 (d, 1H), 8.61 (s, 1H). LRMS: m/z 274 (M-H⁺).

20

EXAMPLE 42


6-[6-(2,5-dimethylpyrrol-1-yl)pyridin-3-yl]-4-propylmorpholin-3-one



Prepared following the same method as for example 27 with the amine from example 41 (1.15g, 4.2mmol). Purification by column chromatography on silica eluting with dichloromethane: methanol (98:2) gave the title compound as a
5 brown film (191mg, 0.61mmol, 14%). ¹H NMR (CDCl₃, 400MHz) δ: 0.97 (t, 3H), 1.65 (m, 2H), 2.13 (s, 6H), 3.38 (m, 1H), 3.42-3.56 (m, 2H), 6.61 (t, 1H), 4.35 (d, 1H), 4.45 (d, 1H), 4.91 (dd, 1H), 6.91 (s, 2H), 7.22 (d, 1H), 7.89 (d, 1H), 8.61 (s, 1H). LRMS: m/z 314 (M-H⁺).

10 EXAMPLE 43

6-[6-(2,5-dimethylpyrrol-1-yl)pyridin-3-yl]-4-propylmorpholine




To a solution of the morpholin-3-one from example 42 (191mg, 0.61mmol) in
15 dry THF (5ml) was added lithium aluminium hydride (1M solution in diethyl ether) (1.25ml, 0.61mmol) and the reaction mixture was warmed to reflux for 2.5 hours. The reaction mixture was cooled to room temperature then 1M NaOH (1.25ml) was added to give a white precipitate. The reaction mixture was filtered and concentrated *in vacuo*. The white solid was discarded. The
20 concentrated filtrate was purified by column chromatography on silica eluting with dichloromethane: methanol (95:5) to give the title compound as a white film (108mg, 0.36mmol, 59%). ¹H NMR (CDCl₃, 400MHz) δ: 0.92 (t, 3H), 1.61

(q, 2H), 2.10 (s, 6H), 2.15 (m, 1H), 2.29 (dt, 1H), 2.40 (t, 2H), 2.82 (d, 1H), 3.02 (d, 1H), 3.90 (t, 1H), 4.08 (d, 1H), 4.71 (d, 1H), 5.89 (s, 2H), 7.20 (d, 1H), 7.81 (d, 1H), 8.60 (s, 1H). LRMS: m/z 300 ($M-H^+$).

5 EXAMPLE 44


5-(4-propylmorpholin-2-yl)pyridin-2-ylamine



To the 2,5-dimethylpyrrole from example 43 (45mg, 0.15mmol) in ethanol (3ml) was added hydroxylamine hydrochloride (52mg, 0.75mmol) and the reaction mixture heated to 80°C for 20 hours. The reaction mixture was cooled to room temperature and concentrated *in vacuo*. The residue was purified by column chromatography on silica eluting with dichloromethane: methanol: ammonia (90:10:1) to give the title compound as a colourless film (31mg, 0.14mmol, 94%). ¹H NMR (CDCl₃, 400MHz) δ : 0.92 (t, 3H), 1.60 (m, 2H), 2.11 (t, 1H), 2.25 (dt, 1H), 2.41 (t, 2H), 2.82-2.91 (dd, 2H), 3.89 (dt, 1H), 4.01 (dd, 1H), 4.57 (bd, 3H), 6.49 (d, 1H), 7.42 (d, 1H), 8.02 (s, 1H). LRMS: m/z 222 ($M-H^+$).

EXAMPLE 45

2-Ethyl-6-(3-methoxy-phenyl)-4-propyl-morpholin-3-one



20


Sodium hydroxide (0.48g, 12.0mmol) in water (2mL) was added to the product from example 3 (0.50g, 2.4mmol) in dichloromethane (5mL) and the mixture stirred at room temperature. 2-Chlorobutyryl chloride (0.28mL, 2.87mmol) was

then added dropwise and the reaction mixture stirred for 60 hours. The reaction mixture was diluted with dichloromethane (10mL) and the aqueous layer was separated. The organic layer was dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the crude product as a clear oil (contained mixture of cyclised and uncyclised material) (0.57g). LRMS: m/z 314 (M-H⁺ of uncyclised material), 296 (M-H⁺ less water), 278 (M-H⁺ of cyclised product). Potassium hydroxide (0.13g, 2.20mmol) was dissolved in water (1mL) and added to a solution of the crude product (0.57g, 1.83mmol) in isopropyl alcohol (5mL). The reaction mixture was stirred at room temperature overnight and the organic solvent then evaporated *in vacuo*. The residue was dissolved in ethyl acetate (10mL) and the aqueous layer separated. The organic layer was dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the crude product as an oil. The residue was purified by column chromatography on silica eluting with ethyl acetate : pentane (1:5 to 1:1) to give the title compound as a clear oil (326mg, 1.17mmol, 49%) as a mixture of diastereomers. ¹H NMR (CDCl₃, 400MHz) δ: 0.90 (t, 3H), 1.00 (t, 3H), 1.60 (m, 2H), 2.00 (bm, 2H), 3.10-3.60 (m, 4H), 3.80 (s, 3H), 4.20 (d, 0.5H), 4.25 (d, 0.5H), 4.75 (d, 0.5H), 4.90 (d, 0.5H), 6.80 (d, 1H), 6.90 (m, 2H), 7.25 (m, 1H). LRMS (APCI): m/z 278 (MH⁺), 276 (MH⁻).

20

EXAMPLES 46A AND 46B

2-Ethyl-6-(3-methoxy-phenyl)-4-propyl-morpholine



Borane-tetrahydrofuran complex (1M in THF) (3mL, 3mmol) was added dropwise to the product from example 45 (0.33g, 1.18mmol) in dry THF (4mL) under an atmosphere of nitrogen. The reaction mixture was heated at 85°C for


3 hours then cooled and quenched by the addition of methanol (1mL). The reaction mixture was then concentrated *in vacuo* and the residue suspended in 6N HCl (aq) (10mL) and heated to 60°C for 1.5 hours. The reaction mixture was cooled and extracted with diethyl ether (2 x 10mL). The aqueous layer was rendered basic (pH 9-10) by addition of solid potassium carbonate before re-extracting with dichloromethane (2 x 15mL). The dichloromethane extracts were dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the crude products as a clear oil. Purification by column chromatography on silica eluting with ethyl acetate: pentane (1:10) yielded the two title compounds as single diastereomers.

Example 46A: clear oil (0.10g, 0.38mmol, 32%): ¹H NMR (CDCl₃, 400MHz) δ: 1.00 (m, 6H), 1.60 (bm, 3H), 1.85 (m, 1H), 2.25 (bt, 2H), 2.35 (s, 1H), 2.45 (m, 1H), 2.60 (m, 1H), 2.65 (m, 1H), 3.70 (s, 1H), 3.80 (s, 3H), 4.80 (s, 1H), 6.80 (d, 1H), 7.00 (m, 2H), 7.25 (m, 1H). LRMS (APCI): m/z 264 (M-H⁺).

Example 46B: clear oil (0.10g, 0.38mmol, 32%): ¹H NMR (CDCl₃, 400MHz) δ: 0.90 (t, 3H), 1.00 (t, 3H), 1.60 (bm, 4H), 1.80 (bs, 1H), 2.00 (bs, 1H), 2.35 (bs, 2H), 2.85 (bd, 1H), 2.95 (bd, 1H), 3.60 (s, 1H), 3.80 (s, 3H), 4.60 (s, 1H), 6.80 (d, 1H), 6.95 (s, 2H), 7.25 (t, 1H). LRMS (APCI): m/z 264 (MH⁺).


20 EXAMPLE 47A

3-(6-Ethyl-4-propyl-morpholin-2-yl)-phenol



Hydrobromic acid (48% aq., 5mL) and the product from example 46A (0.10g, 0.38mmol) were heated at 80°C for 16 hours. After cooling the reaction mixture was concentrated *in vacuo*. The residue was partitioned between aqueous ammonia (0.880, 15mL) and dichloromethane (15mL), the layers were separated and the aqueous layer re-extracted with dichloromethane (2 x 15mL).


The organic extracts were combined, dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo*. The crude product was purified by column chromatography on silica eluting with dichloromethane, then dichloromethane : methanol (99:1 to 95:5) to yield the title compound as a clear oil (65mg, 0.26mmol, 69%) as the single diastereoisomer. ¹H NMR (CDCl₃, 400MHz) δ: 0.95 (m, 6H), 1.60 (m, 3H), 1.85 (m, 1H), 2.25 (m, 2H), 2.45 (m, 2H), 2.55 (q, 1H), 2.75 (d, 1H), 3.75 (s, 1H), 4.80 (m, 1H), 6.70 (d, 1H), 6.90 (s, 1H), 7.00 (1H, d), 7.25 (t, 1H). LRMS (APCI): m/z 250 (MH⁺). Analysis found C, 70.94%; H, 9.16%; N, 5.53%. C₁₅H₂₃NO₂·0.3H₂O requires C, 70.72%; H, 9.34%; N, 5.50%.

EXAMPLE 47B**3-(6-Ethyl-4-propyl-morpholin-2-yl)-phenol**


15

Prepared following the same method as for example 47A with the product from example 46B (0.10g, 0.38mmol). Purification by column chromatography on silica was not required. The title compound was obtained as a yellow oil (57mg, 0.23mmol, 60%) as the single diastereoisomer. ¹H NMR (CDCl₃, 400MHz) δ: 0.90 (t, 3H), 1.00 (t, 3H), 1.60 (m, 4H), 1.85 (t, 1H), 2.00 (t, 1H), 2.35 (m, 2H), 2.90 (d, 1H), 3.00 (d, 1H), 3.65 (m, 1H), 4.60 (m, 1H), 6.75 (d, 1H), 6.80 (s, 1H), 6.90 (1H, d), 7.20 (t, 1H). LRMS (ESI): m/z 250 (MH⁺), 248 (M-H⁻). Analysis found C, 71.63%; H, 9.19%; N, 5.55%. C₁₅H₂₃NO₂·0.1H₂O requires C, 71.73%; H, 9.31%; N, 5.58%.

25

EXAMPLE 48**2-Methyl-6-(3-methoxy-phenyl)-4-propyl-morpholin-3-one**

Prepared following the same method as for example 45 with the product from
5 example 3 (0.44g, 2.10mmol) and 2-chloropropionyl chloride (0.25mL,
2.50mmol). Purification by column chromatography on silica of the title
compound was not required. The title compound was obtained as a clear oil
(0.42g, 1.60mmol, 76%) as a mixture of diastereomers. ¹H NMR (CDCl₃,
400MHz) δ: 0.95 (t, 3H), 1.60 (m, 5H), 3.30 (bm, 2H), 3.50 (bm, 2H), 3.80 (s,
10 3H), 4.40 (q, 0.5H), 4.55 (q, 0.5H), 4.80 (dd, 0.5H), 4.95 (dd, 0.5H), 6.85 (d,
1H), 6.95 (s, 2H), 7.25 (m, 1H). LRMS (APCI): m/z 264 (MH⁺), 262 (MH⁻).

EXAMPLE 49A AND 49B**2-Methyl-6-(3-methoxy-phenyl)-4-propyl-morpholine**


15

Prepared following the same method as for example 46 with the product from
example 48 (0.42g, 1.6mmol). Purification by column chromatography on silica
eluting with ethyl acetate: pentane (1:6) yielded the two title compounds as
single diastereomers.


20 Example 49A: clear oil (0.10g, 0.40mmol, 25%): ¹H NMR (CDCl₃, 400MHz) δ:
0.95 (t 3H), 1.30 (d, 3H), 1.60 (m, 2H), 2.20-2.35 (m, 3H), 2.50 (d, 1H), 2.60 (m,
1H), 2.65 (d, 1H), 3.80 (s, 3H), 4.00 (s, 1H), 4.85 (s, 1H), 6.80 (d, 1H), 7.05 (m,
2H), 7.25 (m, 1H). LRMS (APCI): m/z 250 (MH⁺).

Example 49B: clear oil (0.10g, 0.40mmol, 25%): ^1H NMR (CDCl_3 , 400MHz) δ : 0.90 (t, 3H), 1.25 (m, 3H), 1.60 (m, 2H), 1.80 (m, 1H), 2.00 (bm, 1H), 2.35 (s, 2H), 2.80 (d, 1H), 2.90 (d, 1H), 3.80 (s, 3H), 3.85 (s, 1H), 4.60 (s, 1H), 6.80 (d, 1H), 7.00 (m, 2H), 7.25 (m, 1H). LRMS (APCI): m/z 250 (MH^+).

5


EXAMPLE 50A**3-(6-Methyl-4-propyl-morpholin-2-yl)-phenol**

Prepared following the same method as for example 47A with the product from
10 example 49A (0.10g, 0.4mmol). Purification by column chromatography on
silica eluting with dichloromethane, then dichloromethane : methanol (99:1)
yielded the title compound as a clear oil (70mg, 0.30mmol, 74%) as the single
diastereoisomer. ^1H NMR (CDCl_3 , 400MHz) δ : 0.95 (t, 3H), 1.35 (d, 3H), 1.55
(m, 2H), 2.25 (m, 2H), 2.35 (m, 1H), 2.50 (m, 1H), 2.55 (m, 1H), 2.75 (d, 1H),
15 4.05 (s, 1H), 4.85 (m, 1H), 6.70 (d, 1H), 6.90 (s, 1H), 7.00 (1H, d), 7.20 (t, 1H).
LRMS (APCI): m/z 236 (MH^+). Analysis found C, 70.62%; H, 8.89%; N, 5.95%.
 $\text{C}_{14}\text{H}_{21}\text{NO}_2 \cdot 0.1\text{H}_2\text{O}$ requires C, 70.91%; H, 9.01%; N, 5.91%.


EXAMPLE 50B**20 3-(6-Methyl-4-propyl-morpholin-2-yl)-phenol**

Prepared following the same method as for example 47A with the product from example 49B (0.10g, 0.4mmol). Purification by column chromatography on silica was not required. The title compound was obtained as a yellow oil (100mg, 0.42mmol, 103% - contained 3% starting material) as the single diastereomer. ^1H NMR (CDCl_3 , 400MHz) δ : 0.90 (t, 3H), 1.25 (d, 3H), 1.60 (m, 2H), 1.85 (m, 1H), 2.00 (m, 1H), 2.35 (m, 2H), 2.85 (d, 1H), 3.00 (d, 1H), 3.85 (s, 1H), 4.60 (d, 1H), 6.75 (d, 1H), 6.80 (s, 1H), 6.90 (1H, d), 7.20 (m, 1H). LRMS (APCI): m/z 236 (MH^+). Analysis found C, 69.38%; H, 8.86%; N, 5.73%. $\text{C}_{14}\text{H}_{21}\text{NO}_2 \cdot 0.45\text{H}_2\text{O}$ requires C, 69.33%; H, 9.06%; N, 5.78%.

10

EXAMPLE 51**1-(4-Chloro-3-methoxy-phenyl)-2-propylamino-ethanol**


15 Sodium triacetoxymethylborohydride (1.25g, 5.89mmol) was added with care to a solution of 2-amino-1-(4-chloro-3-methoxy-phenyl)-ethanol (J.Med.Chem., 30(10), 1887, (1987)) (600mg, 2.98mmol) and propionaldehyde (0.22mL, 2.96mmol) in dichloromethane (10mL), and the reaction mixture was stirred at room temperature for 1 hour. Sodium bicarbonate solution (sat. aq., 10mL)
20 was added dropwise and then the reaction mixture was diluted further with water (20mL) and dichloromethane (20mL). The aqueous layer was separated and re-extracted with dichloromethane (2 x 20mL). The combined organic layers were dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo*. The crude product was purified by column
25 chromatography on silica eluting with dichloromethane : methanol : 0.880 ammonia (95:5:0.5 to 92:8:0.8) to yield the title compound as a solid (320mg, 1.31mmol, 44%). ^1H NMR (CDCl_3 , 400MHz) δ : 0.90 (t, 3H), 1.50 (q, 2H), 2.50-2.70 (m, 5H), 2.90 (dd, 1H), 3.80 (s, 3H), 4.65 (dd, 1H), 6.85 (d, 1H), 7.00 (1H, d), 7.30 (bd, 1H). LRMS (APCI): m/z 244 (MH^+), 226 (MH^+ less H_2O).

EXAMPLE 52**6-(4-Chloro-3-methoxy-phenyl)-4-propyl-morpholin-3-one**

- 5 Chloroacetyl chloride (0.11mL, 1.33mmol) was added to a solution of the product from example 51 (0.31g, 1.27mmol) and triethylamine (0.19mL, 1.36mmol) in dichloromethane (10mL) and stirred at room temperature for 60 hours. The reaction mixture was diluted with dichloromethane (20mL) and washed with hydrochloric acid (aq. 1N, 10mL), water (10mL) and sodium
- 10 bicarbonate solution (sat. aq., 10mL). The organic layer was dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to yield the uncyclised product as an oil (0.40g). LRMS (APCI): m/z 320 (MH⁺ of uncyclised product), 302 (MH⁺ less water), 284 (MH⁺ of cyclised product). Potassium hydroxide (0.75g, 1.33mmol) was added to a solution of the uncyclised product
- 15 (0.40g, 1.23mmol) in isopropyl alcohol (10mL) and water (0.4mL) and stirred at room temperature for 16 hours. The reaction mixture was concentrated *in vacuo* and partitioned between dichloromethane (30mL) and water (30mL). The layers were separated and the aqueous layer re-extracted with dichloromethane (2 x 20mL). The combined organics were washed with water
- 20 (30mL), dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to yield the title compound as an oil (0.34g, 1.19mmol, 94%). ¹H NMR (CDCl₃, 400MHz) δ: 0.95 (t, 3H), 1.60-1.70 (m, 2H), 3.30-3.40 (m, 2H), 3.40-3.55 (m, 2H), 3.95 (s, 3H), 4.35 (bd, 1H), 4.42 (bd, 1H), 4.78 (dd, 1H), 6.85 (dd, 1H), 7.00 (s, 1H), 7.38 (dd, 1H). LRMS (APCI): m/z 284 (MH⁺).

25


EXAMPLE 53**6-(4-Chloro-3-methoxy-phenyl)-4-propyl-morpholin-3-one**



Borane-tetrahydrofuran complex (1M in THF) (3.5mL, 3.5mmol) was added dropwise to a solution of the product from example 52 (0.33g, 1.16mmol) in dry THF (3mL) under an atmosphere of nitrogen. The reaction mixture was refluxed for 2.5 hours then cooled and quenched by addition of methanol (1 mL). The reaction mixture was concentrated *in vacuo* and the residue suspended in 4N HCl (aq., 8mL) and refluxed for 2 hours. The reaction mixture was cooled and extracted with dichloromethane (2 x 10mL). The organic layers were discarded. The aqueous layer was rendered basic (pH 9-10) by addition of solid potassium carbonate before re-extracting with dichloromethane (2 x 15mL). The dichloromethane extracts were washed with water (10mL), dried over anhydrous magnesium sulphate, filtered and concentrated *in vacuo* to give the title compound as an oil (0.31g, 1.15mmol, 99%). ¹H NMR (CDCl₃, 400MHz) δ : 0.95 (t, 3H), 1.45-1.60 (m, 2H), 2.00 (t, 1H), 2.20 (t, 1H), 2.35 (t, 2H), 2.80 (d, 1H), 2.90 (d, 1H), 3.80 (t, 1H), 3.90 (s, 3H), 4.03 (dd, 1H), 4.55 (d, 1H), 6.85 (dd, 1H), 7.00 (s, 1H), 7.30 (dd, 1H). LRMS (APCI): m/z 270 (MH⁺).

EXAMPLE 54

2-Chloro-5-(4-propyl-morpholin-2-yl)-phenol



Prepared following the same method as for example 7b (although refluxing was continued for 2.5 hours rather than 1 hour) with the product from example 53 (0.28g, 1.02mmol). Purification by column chromatography on silica was not required. The title compound was yielded as a pale brown gum (0.21g,

0.82mmol, 81%). ^1H NMR (CDCl_3 , 400MHz) δ : 0.93 (t, 3H), 1.55 (q, 2H), 2.0 (t, 1H), 2.20 (dt, 1H), 2.30-2.40 (m, 2H), 2.80 (bd, 1H), 2.90 (bd, 1H), 3.80 (dt, 1H), 4.0 (dd, 1H), 4.30 (d, 1H), 6.87 (dt, 1H), 7.02 (fd, 1H), 7.25 (s, 1H). LRMS (APCI): m/z 256 (MH^+). Analysis found C, 60.71%; H, 7.10%; N, 5.45%.

- 5 $\text{C}_{13}\text{H}_{18}\text{NO}_2\text{Cl}$ requires C, 61.05%; H, 7.09%; N, 5.48%.